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Summary 
 
Protein aggregation is the cause of several human diseases such as diabetes mellitus 
type 2, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, spongiform 
encephalopathies, congestive heart failure or dialysis-related amyloidosis. All of these 
disorders result from protein misfolding which leads to fibrillization and deposition of 
amyloid plaques in different parts of the body.  
Due to high molecular weight of the amyloid fibrils and intrinsic heterogeneity of the 
intermediate states, protein aggregation is a very challenging field of study for the structural 
biologist. However, nuclear magnetic resonance (NMR) provides a unique possibility to 
investigate aggregation at all stages, from the monomer to the fibrils. 
In this work, structural changes involved in prion diseases and dialysis-related 
amyloidosis are investigated with the help of various NMR techniques. 
Prion diseases are caused by the aggregation of the natively α-helical prion protein 
PrPC into its pathological β-sheet-rich isoform PrPSc. While the mechanism of conversion 
remains unclear, several models of PrPSc have been proposed. Most of them originate from 
the assumption that, upon aggregation of the prion protein, helix 1 is converted into β-sheet. 
In Chapter 3, using different stop mutants of the human prion protein, it is shown that no 
such conversion occurs. Moreover, evidence is provided that while helix 1 region promotes 
aggregation of the protein, it is not resistant to proteinase K digestion and therefore not 
converted into a β-strand. Investigation of solvent protection of PrP fibrils reveals increased 
flexibility of helix 1 and β-strand 2 regions and identifies a small, rigid fibrillar core 
comprising four β-strands. Importantly, residues responsible for the species barrier and the 
M/V polymorpshism at codon 129 are found to be deeply buried in the core of humPrP fibrils. 
Furthermore, it is shown that the fibrillar forms of different stop mutants of the human prion 
protein share common structural features. Finally, based on the available data a model for 
PrPSC is proposed. 
 The second protein misfolding diseases studied here is dialysis related amyloidosis. 
The disease is observed in patients with chronic renal failure undergoing long-term 
hemodialysis and is caused by aggregation of beta-2-microglobulin (hβ2m) - the light chain of 
the type I major histocompatibility complex. Due to its low molecular weight (11kDa) and a 
well-defined seven-stranded β-sandwich native fold, hβ2m is considered a very good model 
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for studying all amyloid disorders. In Chapter 4, structural differences between two acid-
denatured intermediate states of hβ2m are shown, and experimental data is presented that 
strongly suggests an effect of the dynamics of the precursor ensembles on the morphology of 
the resulting fibrils. Furthermore, new information on solvent protection of the amyloid 
aggregates is provided and flexible regions within the fibrils of hβ2m are identified. 
 Independent of the above-mentioned projects, a study on the effects of electrostatic 
interactions on molecular alignment of intrinsically unstructured proteins is presented in form 
of a reprint in Appendix A. Weak molecular alignment is required in NMR for observation of 
dipolar couplings, which are a sensitive probe of the structure and dynamics of biomolecules. 
It is demonstrated that alignment of disordered proteins depends critically on electrostatic 
interactions, is scaled with the ionic strength of the solution, and can be predicted using a 
simplified electrostatic model. 
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1. Introduction 
1.1. Protein folding, misfolding and aggregation 
Protein folding is a process in which a newly expressed and post-translationally 
modified polypeptide chain adopts a structural conformation in which the hydrophobic 
elements are buried inside the fold while the hydrophilic ones are exposed on the surface 
(Crick, 1970). This transition is crucial as the right fold is a prerequisite for a protein’s long 
term stability and the ability to selectively interact with its partners (Dobson, 2003). But what 
is the mechanism of folding and how is the native structure adopted? The pioneering work on 
protein folding in the 1970s (Anfinsen, 1973) concluded that the three-dimensional structure 
is encoded in the amino acid sequence of the polypeptide chain and that this functional fold 
should represent a global minimum on the energy landscape. Based on this finding, enormous 
effort has been put in order to understand the process of folding and how the minimum energy 
state is achieved. It became evident that a random search for the right conformation cannot be 
performed on a microsecond to millisecond biological timescale of protein folding, and that 
the protein is rather “funneled” down the energy landscape by energy barriers, kinetic traps 
and narrow pathways (Figure 1-1) (Wolynes et al., 1995; Dill and Chan, 1997). 
 
Figure 1-1. Schematic representation of folding energy landscapes. 
(a) Folding is achieved by a random search through all possible conformations. 
(b) Protein is funneled down the energy landscape through intermediate stages 
(adapted from Dill and Chan, 1997). 
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The presence of metastable intermediates may lead to intermolecular interactions 
between the partially unfolded states and self association into large assemblies known as 
aggregates (Dobson, 2003; Brockwell and Radford, 2007). Therefore, it is necessary for the 
cell that folding is controlled in order to prevent misfolding (Figure 1-2). In a normal 
biological state this is accomplished by molecular chaperones (Hsp) and the ubiquitin-
proteasome pathway which prevent protein unfolding and aggregation by facilitating 
refolding and degradation, respectively (Jahn and Radford, 2005). Impairment of these factors 
results in malfunctioning of the living organism and hence in disease (Thomas et al., 1995; 
Dobson, 2001; Horwich, 2002). 
 
Figure 1-2. Factors influencing protein folding and aggregation in vivo. 
In normal state, molecular chaperones (Hsp) and proteasomal degradation 
pathway prevent protein unfolding or misfolding. Failure of this mechanisms 
results in increased protein aggregation. By self-association of partially folded 
proteins small oligomers are formed which may further assemble into pores, 
protofibrils and mature fibril deposits (adapted from Jahn and Radford, 2005). 
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To current knowledge, more than a 100 diseases in both humans and animals involve 
aggregation of any of twenty non-homologous proteins (Kisilevsky, 1983; Pepys, 1988; 
Jacobson and Buxbaum, 1991; Selkoe, 1997; Kisilevsky, 2000). One of the classes of protein 
aggregation disorders are amyloidoses (see Table 1-1). This group of diseases is directly 
associated with deposition of proteinaceous aggregates in tissues, including the brain, heart, 
spleen, pancreas and skeletal tissue (Kelly and Lansbury, 1994; Tan and Pepys, 1994; 
Horwich, 2002). In many cases, the protein assemblies found in vivo contain a variety of other 
molecules, such as carbohydrates or additional proteins (Dobson, 2003).  
 
Table 1-1. Examples of amyloidoses. 
disease related protein 
Alzheimer’s disease β-amyloid peptide, tau 
Parkinson’s disease α-synuclein 
familial amyloid polyneuropathy transthyretin 
transmissible spongiform encephalopathies prion protein 
Huntington’s disease huntingtin 
frontotemporal dementia  tau 
dialysis related amyloidosis β-2-microglobulin 
diabetes mellitus type II islet amyloid polypeptide 
 
Even though the monomeric soluble forms of disease related proteins range from 
compact globular folds to intrinsically unstructured polypeptides, the aggregated forms share 
many common features. They are able to bind certain dyes such as Thioflavin T or Congo red 
(Elghetany and Saleem, 1988) and exhibit similar morphologies – namely long, unbranched 
and often twisted fibers a few nanometers in diameter, which show a characteristic X-ray 
diffraction pattern. These patterns display typical meridional reflections at ~4.7 Å and 
equatorial reflections at ~10 Å, indicative of a silk-like structure composed of stacked β-
sheets with the strands running perpendicular to the axis of the fibril (cross-β structure). The 
common features of amyloid fibrils are summarized in Figure 1-3. 
 Alternative to the cross-β structure, β-helix and nanotube models have been proposed, 
in which one or more β-sheets wrap around a hollow core in a helical manner. The β-helical 
model was first suggested for fibrils of a short model peptide and showed a cylindrical 
antiparallel β-helix 20 Å in diameter (Lazo and Downing, 1997). The nanotube model, based 
on absence of the 10 Å equatorial reflection, suggested a watter filled tube with internal and 
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external diameters of 12 Å and 32 Å, respectively (Perutz et al., 2002). Beta-helical models 
have also been proposed for the prion protein, based on 2D crystals of the protein extracted 
from brain tissue (Govaerts et al., 2004), and for amyloid-beta peptide, based on hydrogen-
deuterium exchange data and a proline scan experiment (Kheterpal et al., 2000; Williams et 
al., 2004). 
 
Figure 1-3. Characteristics of amyloid proteins. 
(a) EM images of negatively stained amyloid fibrils. (b) X-ray fibre diffraction 
pattern from aligned fibrils formed by islet amyloid polypeptide showing the 4.7 
Å and ~10 Å reflections (adapted from(Makin and Serpell, 2005). (c) A model of 
the cross-β architecture showing the interstrand distance of 4.7 Å and intersheet 
distance of 10 Å (modified from(Jack et al., 2006). 
 
Regarding the origin of the structure of the fibrillar state, the ability to form aggregates 
is regarded an intrinsic physicochemical property of the polypeptide chain, as the amyloid 
structures are mostly stabilized by hydrogen bonds involving the protein backbone (Dobson, 
1999). This is supported by evidence that under specific conditions also non-disease related 
proteins can form fibrils (Guijarro et al., 1998; Chiti et al., 1999).  
Evidence emerges that low molecular weight aggregates are indeed causing the 
toxicity, while appearance of mature fibril deposits is suggested to play a protective role as a 
removal mechanism for the toxic oligomeric intermediates (Snyder et al., 1994; Harper et al., 
1997; Lambert et al., 1998; Klein et al., 2001; Bucciantini et al., 2002; Walsh et al., 2002; 
Yong et al., 2002). In fact, by targeting regions of the protein responsible for further self-
association of oligomeric and protofibrillar species, it is possible to generate mutants with 
increased toxicity which do not form amyloid fibrils (Karpinar DP, unpublished data). 
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However, irrespective of whether the amyloid fibrils or intermediates are the toxic 
species, it is of extreme importance to investigate the structural properties of all stages on the 
aggregation pathway, in order to fully understand the process of amyloid formation and 
enable the development of treatment strategies. It is also very likely, that the structure of 
mature fibrils will shed light on the structure of their precursors. 
 
1.2. NMR methods to study amyloid disorders 
 Due to the large size of the aggregates, dynamic conformational exchange during the 
aggregation process and intrinsic heterogeneity of the high molecular weight assemblies and 
their precursors, studies of protein aggregation present a great challenge to the structural 
biologist. While X-ray crystallography struggles with the insolubility and complexity of the 
fibrils and cryo electron microscopy fails to provide images at atomic resolution, nuclear 
magnetic resonance (NMR) remains the method of choice in investigation of amyloidoses. 
 However, in solution-state NMR spectroscopy, signals originating from fibrils are 
broadened beyond detection and therefore not directly observable. This is caused by increased 
relaxation rates due to contributions from dipolar couplings and chemical shift anisotropy 
(CSA). The dipolar coupling Hamiltionian for a heteronuclear case is given as: 
( ) zzD IIr hH 21233
2
210 ˆˆ1cos3
16
ˆ −−= θπ
γγμ
 
while the chemical shift Hamiltonian is: 
( )( )[ ] zCSisoCS IBH ˆ2cossin1cos31ˆ 220 φθηθσσγ +−Δ+−=  
where Δσ is the chemical shift anisotropy. 
As can be seen from the above equations, both dipolar couplings and CSA depend on the term 
(3cos2θ – 1), which in an isotropic solution is time averaged to 0 as a result of Brownian 
motions. In a rigid amyloid fibril, lack of this free tumbling results in severe line broadening. 
Solid state NMR can overcome these problems, as during the experiment the sample is being 
spun at an angle θm ~ 54.7o, also called the “magic angle”, where (3cos2θ – 1) equals zero. 
Therefore, under magic angle spinning (MAS), CSA and dipolar couplings are removed (if 
the sample is spinning “fast enough”) and spectra with relatively narrow lines can be 
recorded. 
 Numerous solid state NMR spectroscopy studies on amyloid fibrils have been 
performed and provided valuable information about the structure of the aggregates (see(Heise, 
2008)and references therein). Nevertheless, solid-state NMR spectroscopy has also its 
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drawbacks. As opposed to NMR in solution, where protons are the observed nucleus, in solid 
state NMR proton lines are still too broad and the spectra need to be detected on heteronuclei. 
The complexity of solid-state NMR spectra of amyloid fibrils frequently leads to problems 
with completing the assignment, which reflects onto the chemical shift based analysis of 
secondary structure. Although secondary chemical shifts provide useful direct information, it 
may be hard to determine the boundaries of secondary structure elements, especially in case 
of incompletely assigned spectra. Furthermore, selective and site-specific labeling is often 
required to decrease the complexity of the spectrum and since such labeling is not easily 
achievable in recombinantly expressed proteins, many of the solid state studies on amyloid 
fibrils were actually performed on short synthetic peptides rather than the full length protein 
(Jaroniec et al., 2004; Iwata et al., 2006; Walsh et al., 2009). Such approach raises questions 
regarding the preparation of aggregates and selection of the “minimal fragment” still able to 
form fibrils. 
 It may be therefore preferable to work with full-length proteins and use special 
solution-state-NMR-based techniques to get indirect information on the amyloid structure. In 
the past years, two such approaches have proven to be especially useful: quenched 
hydrogen/deuterium (H/D) exchange followed by fibril dissolving and high-resolution magic 
angle spinning (HR-MAS). 
 
1.2.1. Quenched H/D exchange 
The quenched H/D exchange method uses standard solution-state NMR experiments to 
detect residues found in the core of the fibril. It is based on partial solvent protection of the 
hydrogen bonded amide protons throughout the length of the fibril. Backbone amide groups 
located inside the amyloid structure experience lower solvent exchange rates than the ones 
present on the exterior of the fibril (Ippel et al., 2002). A crucial step in the procedure is the 
dissolving of fibrils to monomers, which are observable in the NMR experiment. The 
dissolution needs to be fast and complete in order to prevent back-exchange during the time of 
sample preparation. Commonly used solvents comprise mixtures of DMSO and 
dichloroacetate, which were found to rapidly dissociate amyloid fibrils formed by various 
proteins (Hoshino et al., 2007). An additional convenient feature of DMSO/DCA mixtures is 
that the acidic environment provided by addition of dichloroacetate slows down any exchange 
processes occurring after dissolution of fibrils, therefore allowing for longer NMR 
measurements. 
1. Introduction 
7  
 Practically, the experiment is performed as follows. The fully protonated fibrils are 
collected, washed to remove residual monomer and incubated in D2O over a given period of 
time. The exchange process is quenched by freezing of the sample in liquid nitrogen and 
subsequent lyophilization. This allows for storage of the partially exchanged fibrils until the 
start of the NMR measurement. The fibrils are converted to monomer by addition of ice-cold 
DMSO/DCA mixture and a set of two-dimensional 1H,15N-HSQC spectra is recorded. A 
schematic representation of the procedure is shown in Figure 1-4. 
 
Figure 1-4. Schematic representation of the NMR-detected H/D exchange 
experiment. (a) During the exchange period fully protonated fibrils are incubated 
with D2O. (b) Hydrogen bonded protons in the core (green) are protected from the 
exchange, while protons in flexible parts exchange to deuterium (red). (c) 
Dissolving of fibrils leads to NMR-observable monomers. (d) During the back-
exchange period a set of NMR spectra is recorded over time while the deuterons 
exchange back to protons. 
 
The quenched H/D experiment has been successfully performed on amyloid fibrils of β-
2-microglobulin (Hoshino et al., 2002), transthyretin (Olofsson et al., 2004) and amyloid-β-
(1-42) peptide (Olofsson et al., 2006). Even though the method does not provide a high-
resolution structural model, it leads to residue-specific information on which amino acids are 
involved in the hydrogen-bonding network within the fibril. Detection of the H/D exchange 
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can alternatively by accomplished by mass spectrometry (Lu et al., 2007), however data 
collected in this way is less accurate and relies heavily on the fragmentation of the 
polypeptide chain. NMR-detected experiments have a strong advantage of providing data with 
single residue resolution.  
 
1.2.2. HR-MAS 
 A second technique gaining popularity in studies of amyloid fibrils is high-resolution 
magic angle spinning. Similarly to solid-state NMR, the sample is spun at a speed of up to 19 
kHz in order to remove relaxation contributions from dipolar couplings and CSA. The effect 
of spinning on the observed signal is depicted in Figure 1-5. 
 
Figure 1-5. High-resolution magic angle spinning.  
One-dimensional 1H spectra of (a) human Lipoma tissue (modified from Bruker 
Biospin HR-MAS manual) and (b) amyloid fibrils of the HET-s(218-289) prion 
protein (adapted from Siemer et al., 2006) recorded with (top) and without 
(bottom) magic angle spinning. 
 
HR-MAS experiments utilize the INEPT transfer commonly found in heteronuclear 
pulse schemes for NMR in solution. As a result, in rigid regions of the protein, strong dipolar 
couplings lead to fast relaxation of the magnetization during the transfer and evolution 
periods, and only signals originating from flexible regions are observed in the spectrum. 
Therefore, an HR-MAS spectrum provides information complementary to a dipolar-based 
solid state NMR experiment in which only rigid residues contribute to the recorded signal 
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(Andronesi et al., 2005). Another important consideration in this respect are potential 
problems with obtaining sequence specific assignments. In case of very rigid and compact 
fibrils, only a few resonances may be observable and only chemical shift based assignment of 
residue types may be possible. However in a recent study on the HET-s prion protein, 
complementation of the HR-MAS data by solid state NMR experiments led to partial 
assignment of the flexible regions (Siemer et al., 2006). 
 High-resolution MAS has also the potential to become a powerful tool in 
metabonomics and diagnostic tests of neurodegenerative diseases (Holmes et al., 2006). With 
sample requirements as low as 12 μL for liquid- or ~10 mg in case of solid-type material, HR-
MAS can easily be used on cerebrospinal fluid or tissues from biopsies. The technique has 
already been utilized in cancer studies (Moka et al., 1998; Tate et al., 2000) and very recently 
in the model worm C.elegans, which (if necessary) can be kept alive during the experiment 
(Blaise et al., 2007). 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals 
Cambridge Isotope Laboratories (Andover, USA): 15N-NH4Cl 
Spectra Stable Isotopes (Columbia, USA): 13C-[C6]-D-glucose, D2O  
Sigma-Aldrich (Deisenhofen, Germany): guanidinium thiocyanate, n-dodecyl-penta(ethylene 
glycol) (C12E5), hexanol 
Invitrogen (Karlsruhe, Germany): agarose, Bench Mark protein ladder 
Serva (Heidelberg, Germany): SDS 
Roth (Karlsruhe, Germany): acrylamid, ampicillin sodium salt, APS, dipotassium hydrogen 
phosphate, ethidium bromide, EDTA, guanidinium hydrochloride, HEPES, IPTG, kanamycin, 
potassium dihydrogen phosphate, sodium acetate, sodium deoxychloate, TEMED, tryptone, 
yeast extract 
Roche Diagnostics (Mannheim, Germany): CompleteTM protease inhibitors, CompleteTM 
protease inhibitors EDTA-free, proteinase K 
Merck (Darmstadt, Germany): acetic acid, α-D(+)-glucose monohydrate, ammonium chloride, 
disodium hydrogen phosphate, ethanol, formic acid, glycerol, hydrochloric acid, magnesium 
sulfate heptahydrate, sodium chloride, sodium dihydrogen phosphate, sodium hydroxide, 
thiaminechloride hydrochloride, Tris, urea 
 
2.1.2. Enzymes and DNA-Kits 
Fermentas (Burlington, Canada):  NdeI, BamHI, XhoI, T4-DNA ligase, Pfu DNA polymerase, 
CIA phosphatase 
Finnzymes (Espoo, Finnland): Phusion High Fidelity PCR Master Mix 
Qiagen (Hilden, Germany): Qiagen Plasmid Midi Kit, QIAquick Gel Extraction Kit, 
QIAquick PCR Purification Kit 
Macherey-Nagel (Dueren, Germany): NucleoSpin Extract II Kit, NucleoBond PC 100 Midi 
Kit 
 
2.1.3. Oligonucleotides 
B2M3 (wt hβ2m, forward, NdeI) 
5’- GTC TCT AGA CAT ATG ATC CAG CGT ACT CCA AAG ATT CAG G -3’ 
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B2M2 (wt hβ2m, reverse, BamHI) 
5’- GCT AAG CTT GGA TCC TTA CAT GTC TCG ATC CCA CTT AAC TAT C -3’ 
KM9 (shPrP23-159, forward, NdeI) 
5’- GTC TCT AGA CAT ATG AAG AAG CGG CCA AAG CCT GG -3’ 
KM10 (shPrP23-159, reverse, BamHI) 
5’- GCT AAG CTT GGA TCC TCA GTT AGG GTA GCG GTT CAT GTT TTC -3’ 
All oligonucleotides were purchased from Invitrogen (Karlsruhe, Germany). 
 
2.1.4. Plasmids 
pET26b(+), [ pelB leader; MCS; His-Tag ], 5360 bp, Kanr 
pET27b(+), [ pelB leader; MCS; HSV-Tag; His-Tag ], 5414 bp, Kanr 
pET32a(+), [ Trx-Tag; His-Tag (thrombin); S-Tag (Ek); MCS ], 5900 bp, Ampr 
All vectors were purchased from Novagen (Darmstadt, Germany). 
Table 2-1. Constructs 
Plasmid Coding for Source 
pET27b / humPrP23-159 
human prion protein,   
fragment 23-159 
pET27b / humPrP23-173 
human prion protein,   
fragment 23-173 
kindly provided by Dr. W. Schulz-
Schaeffer, University Hospital, 
Goettingen, Germany 
pQE80LSN_hβ2m human beta-2-microglobulin 
purchased from RZPD,            
Berlin, Germany 
pGX2T-shPrPC(23-231) Syrian hamster prion protein, full length 
kindly provided by Dr. S. Weiss, 
GenCenter, LMU Munich, 
Germany 
pET14b / humPrP23-159 
human prion protein,   
fragment 23-159 this work, Figure 2-1 
pET26b / shPrP23-159 
Syrian hamster prion 
protein, fragment 23-
159 
this work, Figure 2-2 
pET32a / hβ2m human beta-2-microglobulin this work, Figure 2-3 
 
2.1.5. Escherichia coli strains 
XL2-Blue (Stratagene, La Jolla, USA) 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 (Tetr) Amy 
Camr] 
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BL21(DE3) (Novagen, Darmstadt, Germany) 
F- ompT hsdSB(rB–, mB–) gal dcm (DE3) 
 
2.1.6. Chromatography resins 
Ni-NTA agarose, affinity chromatography resin (Qiagen, Hilden, Germany) 
EMD-TMAE Fractogel, anion exchange chromatography resin (Merck, Darmstadt, 
Germany) 
EMD-COO- Fractogel, cation exchange chromatography resin (Merck, Darmstadt, Germany) 
HiLoad 16/60 Superdex 200 prep grade, size-exclusion chromatography column (GE 
Healthcare, Chalfont St. Giles, UK) 
 
2.1.7. Software 
The software used for acquisition of NMR experiments, data analysis and visualization is 
listed in Table 2-2. 
 
Table 2-2. Software 
Name and version Source / Reference 
XWIN-NMR 3.5 Bruker Biospin, Karlsruhe, Germany 
TopSpin 1.0 ~ 2.1 Bruker Biospin, Karlsruhe, Germany 
NMRPipe spin.niddk.nih.gov/NMRPipe (Delaglio et al., 1995) 
Sparky 3 www.cgl.ucsf.edu/home/sparky (Goddard and Kneller) 
MacPyMol DeLano Scientific LLC, Palo Alto, USA 
IgorPro 5.0 WaveMetrics, Portland, USA 
Rosetta++ www.rosettacommons.org 
CS-ROSETTA 
spin.niddk.nih.gov/bax/software/CSROSETTA 
(Shen et al., 2008; Shen et al., 2009) 
PALES www.mpibpc.mpg.de/groups/griesinger/zweckstetter/_links/software_pales.htm 
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2.1.8. Buffers and solutions 
2.1.8.1. Prion protein purification 
Lysis buffer 
100 mM Tris-HCl, 1 M NaCl, 1 mM EDTA, 1 % Triton-X-100, 1 mM benzamidine-HCl, pH 
8.0 
Protease Inhibitor mix 
0.1 mM PMSF, 10 μM TPCK, and 10 μM TLCK in dry methanol 
Inclusion Body wash (IB-wash) buffer 
50 mM Tris-HCl, 23 % sucrose, 1 mM EDTA, 1 mM benzamidine-HCl, 1 % Triton-X-100, 
pH 8.5 
Buffer A 
6 M guanidinium-HCl, 10 mM Tris-HCl, 100 mM sodium phosphate, 15 mM β-
mercaptoethanol, pH 8.0 
Buffer B 
10 mM Tris-HCl, 100 mM sodium phosphate, pH 8.0 
Buffer C 
10 mM Tris-HCl, 100 mM sodium phosphate, pH 5.8 
Buffer E 
10 mM Tris-HCl, 100 mM sodium phosphate, 0.5 M imidazole, pH 5.8 
Buffer W 
20 mM sodium phosphate, 10 mM β-mercaptoethanol, pH 6.0 
 
2.1.8.2. Beta-2-microglobulin purification 
Buffer S1 
50 mM Tris-HCl, 5 % v/v glycerol, 0.1 mM EDTA, 0.1 mM DTT, 50 mM NaCl, pH 7.9 
Buffer W1 
10 mM Tris-HCl, pH 8.0 
Buffer U1 
8 M urea, 10 mM Tris-HCl, pH 8.0 
Buffer GF 
10 mM Tris-HCl, 150 mM NaCl, pH 9.0 
Buffer 10xAG 
250 mM sodium acetate, 250 mM sodium phosphate, pH 2.5 
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NaDOC 
20 % sodium deoxycholate in ddH2O 
 
2.1.8.3. Cell culture media 
Luria-Bertani (LB) broth 
10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O up to 1 L 
M9 minimal medium (per 1 L) 
6.8 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl, 1 g NH4Cl or 15N-NH4Cl, 4 g α-D-glucose or 13C-
[C6]-glucose, 2 mM MgSO4, 0.1 mM CaCl2, 30 mg thiamine-HCl, H2O up to 1 L 
 
 
2.2. Prion protein methods 
2.2.1. Safety considerations 
All expression and purification of human prion protein mutants was carried out under 
S3 conditions, in the laboratory of Dr. Walter Schulz-Schaeffer at the Department of 
Neuropathology of the University Hospital in Goettingen, Germany. Samples of Syrian 
hamster PrP were prepared in the S1 laboratory of the Department of NMR-based Structural 
Biology at the Max-Planck-Institute for Biophysical Chemistry, Goettingen, Germany. 
 
2.2.2. Cloning of His6-tagged humPrP23-159 
The pET27b/humPrP23-159 (see Table 2-1) and target pET14b plasmid DNA were 
digested with 2 units of NdeI endonuclease per μg of DNA. The reaction was carried out at 37 
oC overnight. The digestion products were purified using the MN Nucleospin Extract II Kit 
following the PCR Product Purification protocol of the supplier, and further cleaved for 2 
hours at 37 oC with 2 units of XhoI endonuclease per μg of DNA. After digestion, 1 μL of 
CIA (Calf intestinal alkaline) phosphatase was added to the pET14b vector sample and 
incubated for 30 minutes at 37 oC, while the digested pET27b/humPrP23-159 DNA was stored 
on ice. The reaction mixtures were separated on a 1 % agarose gel for 1 hour at 70 V. Bands 
of pET14b vector and humPrP23-159 insert were excised from the gel and DNA was purified 
using the MN Nucleospin Extract II Kit following the Gel Extraction protocol of the supplier. 
The insert and vector DNA were ligated overnight at 14 oC in presence of 1 Weiss unit of T4 
DNA ligase. Afterwards the ligation mixture was transformed into XL2-Blue CaCl2-
competent E.coli strain and the cells were plated out onto an agar plate containing 100 μg/ml 
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Ampicillin. After an overnight incubation at 37 oC, six colonies were picked from the plate to 
start 20 ml cultures from which plasmid DNA was isolated using the MN NucleoBond PC 
100 Midi Kit and controlled by DNA-sequencing (SeqLab, Goettingen, Germany). Vector 
map of the pET14b-humPrP23-159 construct is shown in Figure 2-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. Vector map of pET14b plasmid coding for humPrP23-159. 
 
2.2.3. Cloning of shPrP23-159 
The open reading frame (ORF) coding for shPrP23-159 was amplified from the plasmid 
pGX2T-shPrPC(23-231) using the primers KM9 and KM10 and the Phusion High Fidelity 
PCR Master Mix. The PCR amplification was done on a Hybaid PCR Sprint thermal cycler 
(Thermo Fisher Scientific, Waltham, USA) using the following cycling conditions: 
  94 oC  -  2 min 
  94 oC  -  30 sec; 55oC  -  30 sec; 72oC  -  1 min / 30 cycles 
  72 oC  -  10 min 
PCR products were separated on a 1 % agarose gel at 70 V and purified using the MN 
NucleoSpin Extract II Kit. The amplified ORF and pET26b vector were then digested with 
NdeI and BamHI restriction endonucleases, ligated, and transformed into XL2-Blue as 
described in 2.2.2. Six clones were picked from the agar plate (containing 50 μg/ml 
Kanamycin) and tested by colony PCR using the HotStarTaq Kit (Qiagen, Hilden, Germany). 
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Two positive clones were selected and verified by DNA sequencing (SeqLab, Goettingen, 
Germany). Vector map of the pET26b-shPrP23-159 is shown in Figure 2-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2. Vector map of pET26b plasmid coding for shPrP23-159. 
 
2.2.4. Expression of prion protein mutants for NMR 
Independent of the construct used, plasmid DNA was freshly transformed into BL21 
(DE3) and cells were grown on selective agar plates. A single colony was picked from the 
plate and a 10 ml overnight culture in LB was started. Next morning cells were pelleted at 
3000 x g,     4 oC for 10 minutes (Beckmann JA17) and resuspended in 1 liter of M9 minimal 
medium containing (if required) 15N-NH4Cl and 13C-[C6]-glucose to obtain uniformly 13C 
and/or 15N labeled proteins. Protein expression was induced at OD600 = 1.0-1.1 by addition of 
IPTG to a final concentration of 1 mM. After induction, the cells were grown for 8 hours, 
spun down at 8000 x g, 4 oC for 15 minutes (Kendro Multifuge 3R) and stored at -80 oC. 
 
2.2.5. Purification of non-tagged prion protein 
Non-tagged prion protein constructs (both human and Syrian hamster) were purified 
according to a common protocol as follows: 
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2.2.5.1. Isolation of inclusion bodies 
The bacterial pellet was resuspended in 30 ml of Lysis buffer supplemented with 300 
μl Protease Inhibitor mix, 3 mg DNase I, 3 mg RNase A, 10 mM CaCl2 and 10 mM MgCl2 
(per liter of M9 medium). Cells were disrupted by three freeze/thaw cycles in liquid nitrogen 
and inclusion bodies were pelleted at 30000 x g, 4 oC for 30 minutes (Beckmann JA17). The 
inclusion bodies were then washed (2-3 times) in a homogenizer with IB-wash buffer 
supplemented with 2 M NaCl and centrifuged at 30000 x g, 4 oC for 30 minutes. Finally, the 
inclusion bodies were washed once with IB-wash buffer supplemented with 0.5 % 
Sulfobetaine 14. 
 
2.2.5.2. Extraction of protein from inclusion bodies 
Purified inclusion bodies were resolubilized in buffer A and centrifuged at 30000 x g, 
4 oC for 30 minutes in order to remove any guanidinium-insoluble particles. The supernatant 
was then transferred into a new tube and a second centrifugation round was performed. The 
prion protein was found solely in the supernatant. 
 
2.2.5.3. Purification by chromatography methods 
A. Affinity chromatography 
Ni-NTA agarose resin was equilibrated with buffer A and the prion protein was bound 
to the resin by incubation at room temperature for 30 minutes. N-terminally truncated protein 
not containing the histidine-rich octarepeat region and nucleic acids were removed by 
washing the resin with buffer A containing 10 mM imidazole and prion protein was eluted in 
a 1:1 mixture of buffers A and 1 M imidazole, pH 7.5. The protein was precipitated by 
addition of 4 volumes of methanol and an overnight incubation at -20 oC. 
B. Anion exchange chromatography 
After centrifugation at 7800 x g, 4 oC for 10 minutes, the protein was resolubilized in 8 
M urea, 20 mM sodium phosphate, 10 mM β-mercaptoethanol, pH 8.0 and loaded onto a 
EMD-TMAE Fractogel anion exchange resin (Merck, Darmstadt, Germany) equilibrated with 
the same buffer. Under this conditions, no binding of the prion protein to the resin occurred. 
C. Cation exchange chromatography 
The PrP-containing flow-through from the anion exchanger was subjected to a EMD-
COO- Fractogel cation exchange resin (Merck, Darmstadt, Germany) equilibrated with 8 M 
urea in 20 mM sodium phosphate, 10 mM β-mercaptoethanol, pH 8.0. Urea was removed by 
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washing the resin with buffer W and the protein was eluted with increasing concentrations 
(0.5 M, 1 M, 6 M) of guanidinium-hydrochloride (GdnHCl) in buffer W. Fractions containing 
prion protein were combined, solid GdnHCl was added to a final concentration of 6 M and the 
pH was adjusted to 8.0. 
 
2.2.5.4. Refolding of the prion protein 
The purified prion protein was bound to Ni-NTA resin as described in 2.2.5.3.A and 
washed in batch mode with a gradient of buffer B in buffer A, such that the GdnHCl 
concentration was decreasing from 6 M to 0 M in 1 M steps. Next, the resin was washed with 
buffer C and the protein was finally eluted with buffer E. Immediately after elution, the 
protein was dialyzed 3 times against 5 liters of 5 mM sodium acetate, pH 4.5 to remove the 
aggregation inducing phosphate buffer. 
 
2.2.6. Fast purification of non-tagged prion proteins 
Since for many NMR experiments, protein purity of about 90% is satisfactory, a 
shorter purification protocol, omitting the ion-exchange chromatography steps, has been 
developed. 
The bacterial pellets (see 2.2.4) were resuspended in 30 ml of buffer B containing 3 
mg DNase I and 3 mg RNase A, and cells were disrupted by three freeze/thaw cycles. 
Inclusion bodies were pelleted by centrifugation for 30 minutes at 30000 x g, 4 oC, and 
washed twice with 30 ml buffer B. The protein was then extracted and preliminarily purified 
from DNA and RNA as described in 2.2.5.2 and 2.2.5.3.A. On the next day, the methanol-
precipitated protein was resolubilized in buffer A, re-subjected to a fresh Ni-NTA resin, and 
refolded as outlined in 2.2.5.4. 
 
2.2.7. Purification of His6-tagged humPrP23-159 
2.2.7.1. Refolding on an affinity column 
The N-terminally tagged humPrP23-159 protein was extracted from inclusion bodies as 
described in 2.2.5.1-2. The protein was then bound to ~5 ml of Ni-NTA resin (equilibrated 
with buffer A) by incubation at room temperature for 1 hour on a rocking shaker. In the first 
step, the resin was washed with 10 volumes of buffer A, and afterwards a 180 ml gradient of 
buffer A to buffer B was applied to refold the protein. Impurities were removed by washing 
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the resin with 50 ml of buffer B containing 50 mM imidazole. In the last step, the resin was 
washed with buffer C followed by elution of the His6-tagged protein in buffer E. 
 
2.2.7.2. Cleavage of the histidine tag 
The eluate was dialysed twice against 10 mM sodium acetate pH 4.5 to remove 
phosphate buffer and decrease the ionic strength of the solution and then twice against 10 mM 
Tris-HCl, pH 8.0 to provide convenient conditions for the cleavage reaction. The histidine tail 
was completely cleaved off in one hour at room temperature with 10 units of thrombin (GE 
Healthcare, Chalfont St. Gilles, UK) per 1 mg of tagged protein, while no cleavage of 
humPrP23-159 occurred under these conditions. After the reaction, solid GdnHCl was added to 
the solution to a final concentration of 6 M to denature thrombin and allow for binding to Ni-
NTA resin. By repeating the refolding protocol described in 2.2.5.4, thrombin could be fully 
removed during the washing steps while humPrP23-159 was eluted in buffer E and dialyzed 
against 5 mM sodium acetate, pH 4.5. 
 
2.2.8. Aggregation 
The aggregation process was initiated by addition of a 10 times concentrated 
phosphate buffer (500 mM potassium phosphate, pH 6.5) to a 400 μM prion protein solution. 
The pH was controlled with an Aldrich microelectrode (Sigma-Aldrich, Deisenhofen, 
Germany) and the reaction mixture was incubated at room temperature in a Stuart SB3 rotator 
(Bibby Scientific, Staffordshire, UK) operating at a speed of 8 rpm. 
 
2.2.9. H/D exchange 
After the aggregation process was completed, fibrils were collected by centrifugation 
and washed twice with the aggregation buffer in order to remove residual monomeric protein. 
Finally, the fibrils were resuspended in 0.1 % formic acid in D2O, pD 2.5 and incubated for a 
given amount of time – 1, 2, 3 and 7 days for humPrP23-159 and 7 days for humPrP23-173. The 
exchange was stopped by rapid freezing of the samples in liquid nitrogen and lyophilization. 
 
2.3. Beta-2-microglobulin methods 
2.3.1. Cloning of hβ2m into pET32a 
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cDNA coding for human β-2-microglobulin was amplified by PCR from the 
pQE80LSN_hβ2m vector (Table 2-1) using primers B2M2 and B2M3 and the following 
cycling conditions: 
 95 oC  -  30 sec 
 95 oC  -  30 sec; 57oC  -  1 min; 72oC  -  1 min / 25 cycles 
 72 oC  -  5 min 
The PCR product was separated in 1 % agarose gel at 70 V and purified using QIAquick PCR 
Purification Kit. The fragment was then digested with 2 U of NdeI endonuclease per μg DNA 
(37 oC overnight), purified again using the QIAquick Kit and digested with 2 U per μg DNA 
of BamHI restriction enzyme (2 hours at 37oC). The target pET32a vector was cleaved with 
NdeI and BamHI in the same manner, and subsequently incubated with 1 μL of CIA 
phosphatase in order to dephosphorylate the 5’ ends and prevent self religation of the vector. 
The vector and insert were then ligated overnight at 14 oC in the presence of 1 Weiss unit of 
T4 DNA Ligase, transformed into XL2-Blue and plated out onto agar plates containing 100 
μg/ml Ampicillin. Six colonies were picked from the plate to start 100 mL cultures in LB 
medium, and plasmid DNA was isolated using the QIAGEN Plasmid DNA Midi Kit. The 
DNA was verified by sequencing (SeqLab, Goettingen, Germany) and transformed into 
BL21(DE3) E.coli strain from which glycerol stocks were prepared and stored at -80 oC. 
Vector map of the pET32a-hβ2m construct is depicted in Figure 2-3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3. Vector map of pET32a plasmid coding for human beta-2-
microglobulin. 
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2.3.2. Protein expression 
2.3.2.1. Expression in LB medium 
The BL21(DE3) cells carrying the pET32a-hβ2m construct were grown on a fresh 
agar/Ampicillin plate from the glycerol stock, and a single colony was picked to start a 20 mL 
overnight culture in LB, which was transferred into 750 mL of the medium the next morning. 
Cells were grown at 37 oC to an OD600 of 0.6 and protein expression was induced by addition 
of IPTG to a final concentration of 1 mM. Following induction, the culture was incubated for 
6 hours at 37 oC and cells were collected by centrifugation at 8000 x g, 4 oC, 15 minutes 
(Beckman J-20) and stored at -80 oC. 
 
2.3.2.2. Expression in M9 minimal medium 
Similarly to the expression protocol in LB, the cells from the glycerol stock were 
grown on a fresh agar/Ampicillin plate and a single colony was picked to start a day culture in 
2 mL of LB medium, which was then used to inoculate a 50 mL overnight culture in M9 
medium. The next day, the overnight culture was transferred into 1 liter of M9 minimal 
medium, which contained 15N-NH4Cl and if required 13C-glucose in order to obtain uniformly 
15N- or 13C15N-labeled protein. At an OD600 = 0.7-0.8, protein expression was induced. Eight 
hours after induction the cells were harvested and stored at -80 oC. 
 
2.3.3. Purification of hβ2m 
2.3.3.1. Isolation from inclusion bodies 
The frozen cell pellet was resuspended in 30 ml of buffer S1 and sonicated 5 times for 
20 seconds using a Bandelin Sonopuls HD2200 sonicator equipped with a UW2200 horn, 
SH213G probe and a 12.7 mm TT13 sonotrode (Bandelin electronic, Berlin, Germany). After 
sonication, sodium deoxycholate was added to the sample to a final concentration of 2 % 
(w/v) and the mixture was incubated on ice for 10 minutes. β-2-microglobulin is secreted in 
the BL21(DE3) strain into inclusion bodies, which after disruption of the cells were collected 
by centrifugation at 20000 x g, 4 oC for 10 minutes (Beckman J-20) and washed three times 
with buffer W1. The inclusion body pellet was then resolubized by stirring in 20 mL of buffer 
U1 for 1 hour at room temperature. The urea-denaturated protein was cleared from any 
insoluble contaminants by centrifugation at 48000 x g, 4 oC for 30 minutes (Beckman Avanti 
J-30I). 
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2.3.3.2. Refolding by dialysis 
Refolding of hβ2m was achieved by removal of denaturant during dialysis. As more 
than 50-fold excess of buffer led to partial precipitation of the protein, dialysis was performed 
twice against 1 liter of 10 mM Tris, pH 8.0 using a Spectra/Por Cellulose Ester 3500 MWCO 
membrane (Spectrum Laboratories, Rancho Dominguez, USA). 
 
2.3.3.3. Size-exclusion chromatography 
After the removal of denaturant, the sample was dialyzed twice against 1 liter of buffer 
GF, sterile filtered and concentrated to <16 mL in a Vivaspin 20, 5000 MWCO concentrator 
(Vivaproducts, Littleton, USA). The protein was then loaded onto a HiLoad 16/60 Superdex 
200 column installed on an ÄKTA purifier FPLC system (GE Healthcare, Chalfont St. Gilles, 
UK) and separated in a 0.5 mL/min flow of buffer GF. Fractions containing monomeric hβ2m 
were pooled, concentrated to 200-250 μM, dialyzed against water and stored at 4 oC.  
 
2.3.4. Preparation of amyloid fibrils 
Aggregation of hβ2m was carried out at 37 oC in 25 mM phosphate, 25 mM acetate 
buffer, pH 2.5 with agitation at 500 rpm in an Eppendorf Thermomixer comfort (Eppendorf, 
Hamburg, Germany). The samples were prepared by addition of 10xAG buffer and water such 
that the final protein concentration was 100 μM in 1xAG buffer. Prior to incubation, the 
solution was sterile filtered and the pH value was controlled with an Aldrich glass 
microelectrode (Sigma-Aldrich, Deisenhofen, Germany). 
 
2.3.5. H/D exchange 
Proton / deuterium exchange in the fibrillar state was performed as described in 2.2.9. 
The exchange time for hβ2m fibrils was 7 days. 
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2.4. NMR spectroscopy 
2.4.1. Backbone resonance assignments 
During the course of this work, several backbone assignments of β-2-microglobulin 
and the prion protein mutants were obtained. The sample conditions and corresponding NMR 
experiments used for assignment are listed in Table 2-3.  
 
Table 2-3. Experiments used for backbone resonance assignments 
Protein Sample conditions NMR experiments Comments 
humPrP23-159 10 mM sodium acetate, pH 4.5 
(HA)CANNH, 
HNCO 
based on BMRB 
entry 4402 
 10 mM sodium acetate, pH 6.5 (HA)CANNH 
based on 
assignment at pH 
4.5 
 
2 M GdnSCN, 0.1 % formic 
acid, 50% H2O / 50% D2O, pH 
3.0 
HNN, HNCACB  
humPrP23-173 10 mM sodium acetate, pH 4.5 (HA)CANNH  
 2 M GdnSCN, 0.1% formic acid,  50 % H2O / 50 % D2O, pH 3.0 
HNN, HNCACB  
hβ2m in pure water, pH 2.5 (HA)CANNH, HNCO 
based on 
assignment by 
Katou et al., 2002 
 in pure water, pH 3.6 13C-detected CON 
only 13C’ and 15N 
resonances 
assigned 
 25 mM sodium phosphate, pH 7.0 HNCA 
based on BMRB 
entry 5169 
 
4 M GdnSCN, 0.1 % formic 
acid, 50% H2O, 50% D2O, pH 
3.0 
HNN, HNCACB, 
CBCA(CO)NH  
hβ2m fibrils 25 mM sodium phosphate, 25 mM sodium acetale, pH 2.5 
2D planes of 
HNCO and HNCA  
 
In general, conventional 3D experiments such as HNCACB, CBCA(CO)NH, HNCO 
and (HA)CANNH were applied. In case conditions facilitating unfolding were used and 
increased spectral overlap in the 1H-15N plane was observed, the 1H and 15N backbone 
resonances were assigned with the HNN experiment shown in Figure 2-4 (Panchal et al., 
2001). 
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Figure 2-4. HNN pulse sequence.  
Narrow and wide pulses correspond to 90o and 180o flip angles, respectively, with 
phase x unless indicated. Water suppression is achieved by a flip-back pulse in the 
first INEPT. The delays are: λ = 2.7 ms, κ = 5.4 ms, δ = 0.35 ms, A = t1/2, B = 
TN, C = TN-t1/2, D = t2/2, E = TN, and F = t2/2. Phase cycling for the experiment 
is: Φ1 = 2(x), 2(-x); Φ2 = x, -x, -x, x; and Φrec = 2(x), 2(-x); (adapted from Panchal 
et al., 2001). 
 
Assignments of human prion protein mutants at pH 4.5 were aided with the chemical 
shift list of humPrP23-230 deposited in the Biological Magnetic Resonance Bank (BMRB, 
http://www.bmrb.wisc.edu) under accession number 4402. 
 
Assignment of hβ2m at pH 3.6 was obtained based on chemical shift changes in the 13C-
detected CON experiment (Figure 2-5) (Bermel et al., 2006) upon a 6-step titration of NaOH 
from pH 2.5 to pH 3.6. 
Signals of hβ2m fibrils observed under HR-MAS were assigned from 2D projections of 
HNCA and HNCO experiments, and by comparison of the fibril spectrum with the spectrum 
of monomeric hβ2m at pH 2.5. 
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Figure 2-5. Pulse sequence of 13C-detected CON-IPAP. 
Narrow and wide pulses correspond to 90o and 180o flip angles, respectively, with 
phase x unless indicated. The gray colored shape indicates an adiabatic pulse. The 
delay λ = 12.5 ms. Selection of in-phase (IP) and anti-phase (AP) components is 
done by changing the duration of delays A, B, C, D. For IP spectrum the delays 
are: A = B = C = D = 6.25 ms, and for the AP spectrum: A = 4.5 ms; B = 8 ms; C 
= D = 6.25 ms. The phase cycle for the experiment is: Φ1 = x, -x; Φ2 = 2(x), 2(-x); 
Φ3 = 4(x), 4(-x); ΦIPAP(IP) = x; ΦIPAP(AP) = -y; and Φrec = x, -x, x, -x, -x, x, -x, x; 
(adapted from Bermel et al., 2006). 
 
2.4.2. Secondary structure determination 
Regions of secondary structure or propensities for adopting a certain conformation can 
be detected by secondary chemical shifts (SCS), which are calculated as the difference 
between the experimentally observed chemical shift and the random coil chemical shift. 
Random coil values used in the calculation were taken from literature (Wishart et al., 1995; 
Schwarzinger et al., 2001). 
 
2.4.3. High-resolution magic angle spinning 
The sample for high-resolution magic angle spinning was prepared by placing 10 mg 
of uniformly 13C,15N-labeled hβ2m fibrils in a BL4 50 μL Teflon rotor (Bruker Biospin, 
Karlsruhe, Germany). All spectra were measured under MAS at 7.2 kHz on a 900 MHz 
Bruker AVANCE spectrometer equipped with a 4 mm HR-MAS probe with Z-gradients. 
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2.4.4. Measurement of diffusion coefficients 
The diffusion coefficient of hβ2m fibrils under HR-MAS was measured by pulse field 
gradient NMR using the LED pulse sequence with a bipolar gradient pulse pair and two spoil 
gradients (Figure 2-6). Residual water and 1,4-dioxane were used as the internal, and bovine 
serum albumin as the external reference. Signal decay curves for the protein were plotted after 
integration of both the amide and the aliphatic regions of the spectrum. The decay curves 
were fitted to a single exponential function and corresponding diffusion coefficients were 
calculated using the external reference values, while the internal reference was used to verify 
that no change in experimental conditions occurred in between the two measurements. 
 
 
 
 
 
 
 
 
Figure 2-6. Pulse sequence of LED sequence with bipolar gradients. 
Narrow and wide pulses correspond to 90o and 180o flip angles, respectively, with 
phase x unless indicated. The length of the diffusion labeling gradient G1 was 0.5 
ms and it’s strength varied from 2 to 95 %, with the diffusion delay Δ = 50 ms and 
the eddy current delay Te = 5 ms. The phase cycle is: Φ1 = 2(x), 2(-x); Φ2 = 4(x), 
4(-x), 4(y), 4(-y); Φ3 = 2(x, -x), 2(-x, x), 2(y, -y), 2(-y, y); Φrec = x, -x, -x, x, -x, x, 
x, -x, y, -y, -y, y, -y, y, y, -y; (adapted from(Wu et al., 1995). 
 
2.4.5. Residual dipolar couplings 
Residual dipolar couplings were determined in presence of n-alkyl-poly(ethylene 
glycol) (C12E5) / hexanol mixture as cosolvent (Ruckert and Otting, 2000), using the IPAP-
HSQC pulse sequence (Ottiger et al., 1998). First, the J-couplings were measured as splittings 
in the 15N dimension of the IPAP-HSQC in an isotropic solution of the protein. Then partial 
alignment was introduced by addition of C12E5 to a concentration of 5% (w/v) and 
subsequent titration of n-hexanol until a splitting in a 1D 2H spectrum was observed. The 
spectrum was remeasured and the 1DNH dipolar couplings were calculated as the difference 
between the splitting measured in the anisotropic condition and the J-couplings measured in 
absence of alignment. 
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2.4.6. NMR-detection of H/D exchange rates 
Prior to the measurement of H/D exchange rates, the temperature in the sample 
chamber of the spectrometer was set to 278 K, and probehead tuning and matching was 
performed on an aliquot of precooled fibril dissolving buffer. The sample was then prepared 
by resolubilizing the lyophilized exchanged fibrils in 250 μL of precooled dissolving buffer 
followed by a brief centrifugation for 10 seconds at top speed in a table-top centrifuge 
(Eppendorf, Hamburg, Germany). The sample was then transferred to a Shigemi NMR tube 
and transported on ice to the spectrometer. To monitor the back-exchange process in the 
monomeric state, a series of 1H,15N-HSQC spectra was recorded over a period of 24 hours 
with each spectrum acquired with 1024 x 512 complex points and 4 transients per increment 
(experiment time of 46 minutes). The “dead time” for sample preparation and experiment 
setup was typically 10-15 minutes. 
Changes in peak intensity during the back-exchange process were then analyzed and 
fitted to a single exponential function. The protection map was subsequently generated by 
plotting the normalized intensity at the end of the experiment series (I24h/I0) against the 
sequence. 
 
2.4.7. Structural predictions with CS-Rosetta 
Predictions with CS-Rosetta were generally run according to the authors’ manual 
provided at spin.niddk.nih.gov/bax/software/CSROSETTA/index.html. Minor alterations in 
the executable scripts were necessary for proper functioning of the package. These included 
usage of “fasta” and “non-fasta” NR databases and changes in checkpoint definition for 
psipred. 
 
2.4.7.1. MFR fragment selection 
In the MFR mode, 200 fragments were selected and used for the subsequent 
ROSETTA structure prediction, and all full-atom models were evaluated by chemical shift 
rescoring. In case of the “triplicate” fragment (see 3.2.4.1), the energy terms for residues in 
the Gly-Ser linkers were excluded from the ROSETTA full-atom energy. Finally, the 
chemical shift based energy rescoring was applied using the script runCSrescore.com 
provided in the installation package. 
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2.4.7.2. Hybrid fragment selection 
To run CS-Rosetta in hybrid mode, new databases of idealized protein structures 
(vall.dat.apr24), pdb files (PDBH.hyb), chemical shift lists (CS.hyb), and idealized backbone 
torsion angles (ANGLESS.hyb) needed to be modified by the authors. Due to problems with 
fragment assembly, the initial fragment candidate files containing 2000 hybrid fragments 
($TAG$PDB$CHAIN09_05.000_v1_3 and $TAG$PDB$CHAIN03_05.000_v1_3) were 
generated by Dr. Yang Shen at the National Institute for Diabetes and Digestive and Kidney 
Diseases, Maryland, USA. The fragment candidates were then scored with the script 
rosettaFrag2csFrag and 200 fragments with best chemical shift scores were kept for each 3- 
and 9-residue target fragment. 
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3. Human prion protein 
3.1. Introduction 
3.1.1. Transmissible spongiform encephalopathies 
 Transmissible spongiform encephalopathies (TSE), also termed “prion diseases”, are a 
group of rare fatal neurodegenerative disorders in humans and animals (Tables 3-1 and 3-2). 
The first cases of TSEs were observed more than 200 years ago in sheep, however it was 
about 20 years ago when prion diseases attracted public attention due to an outbreak of bovine 
spongiform encephalopathy (BSE) or “mad cow disease” in the United Kingdom, and several 
other European countries. 
 Prion diseases are characterized by progressive lesions with vacuolation in the brain, 
massive loss of neuronal cells and appearance of activated astrocytes (astrogliosis) (Brown 
and Gajdusek, 1991). However, the most distinct hallmark of TSE diseases is the 
accumulation of proteinaceous fibrils or “prion rods” in the central nervous system (Merz et 
al., 1981; Prusiner et al., 1983). These deposits consist mainly of the scrapie form of prion 
protein, PrPSC, which is an isoform of host-encoded PrP (Bueler et al., 1993). While the 
incubation periods of TSEs may range from months to several years, after occurrence of 
clinical symptoms the disease rapidly progresses and leads to death in 3-6 months (Chesebro, 
2003). 
 Prion diseases in animals have been identified in sheep, goat, cattle, mink, deer, elk 
and wild cats living in captivity (see Table 3-1). In humans, TSE diseases such as 
Creutzfeldt-Jakob disease (CJD) (Creutzfeldt, 1920; Jakob, 1921), Gerstmann-Sträussler-
Scheinker syndrome (GSS) (Gerstmann et al., 1936) or kuru (Gajdusek and Zigas, 1957) 
comprise three groups of disorders: familial, transmitted and sporadic ones (Table 3-2). 
Table 3-1. Prion diseases in animals 
Disease Animal Etiology First case 
Scrapie sheep, goat infection 1732 
Transmissible Mink Encephalopathy (TME) mink infection 1947 
Chronic Wasting Disease (CWD) deer, elk infection 1967 
Bovine Spongiform Encephalopathy (BSE) cow infection 1985 
Feline Spongiform Encephalopathy (FSE) cats infection 1990 
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Sporadic CJD (sCJD) occurs at an incidence of 1 in 1 million people worldwide and 
accounts for 90% of TSE cases in humans (Masters and Richardson, 1978). The origin of 
sCJD is unknown as no mutations in the PrP-coding gene were found, and there is no 
epidemiological evidence for contact with people or animals with TSE disease (Harries-Jones 
et al., 1988; Will, 1993). 
In about 10% cases, the prion disease occurrence has been attributed to either a PrP 
point mutation or insertions of octapeptide repeats. At present, 42 mutations in the Prnp gene 
are known, 20 of which are causative. Mutation-associated TSE diseases include familial 
CJD, GSS and fatal familial insomnia (FFI). Interestingly, clinical variability occurs even in 
patients of the same family, which suggests that other genes or non-genetic factors may play a 
role in these diseases (Masters et al., 1981; Chapman et al., 1993). 
Table 3-2. Human prion diseases 
Disease Etiology First case 
sporadic Creutzfeldt-Jakob disease (sCJD) unknown 1920/21 
familial Creutzfeldt-Jakob disease (fCJD) PrP mutation 1924 
Gerstmann-Sträussler-Scheinker syndrome (GSS) PrP mutation 1928 
Kuru infection 1956 
iatrogenic Creutzfeldt-Jakob disease (iCJD) infection 1974 
Fatal familal insomnia (FFI) PrP mutation 1992 
variant Creutzfeldt-Jakob disease (vCJD) infection 1995 
 
The group of transmitted TSEs includes kuru, iatrogenic (iCJD) and variant 
Creutzfeldt-Jakob disease (vCJD) and accounts to less than 1 % of all cases. Patients with 
iCJD develop the disease as a result of a surgical procedure during which they were infected 
with contaminated surgical instruments or received a tissue transplant from a donor with non 
diagnosed prion disease (Duffy et al., 1974; Bernoulli et al., 1977; Brown et al., 1992). About 
90 cases of iCJD occurred after treatment with human growth hormone, which was pooled 
from large groups of individuals (Fradkin et al., 1991; Billette de Villemeur et al., 1996). 
Infectious prions in kuru disease were transmitted by ritualistic cannibalism and the disease 
disappeared when these rituals were ceased (Gajdusek and Zigas, 1957; Gajdusek, 1977). A 
few years after the epidemic occurrence of BSE in the UK, cases of a new variant of CJD 
have been observed (Figure 3-1) (Will et al., 1996). Experimental data indicated that this 
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variant CJD and BSE are caused by the same prion strain (Hill et al., 1997) and it is now 
believed that vCJD is the human counterpart of BSE. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Comparison of the incidence of BSE in cattle and vCJD in humans 
(adapted from Chesebro, 2003). 
 
3.1.2. The “protein only” hypothesis 
 For many years after the first description of TSE in humans by Creutzfeldt and Jakob, 
it was believed that prion diseases are caused by a “slow virus” (Sigurdsson, 1954; Hadlow, 
1959; Klatzo et al., 1959; Gajdusek et al., 1966). With increasing knowledge of the diseases, 
it became clear that such a virus would need to have very special properties. Although short 
nucleic acid fragments have been found in scrapie prion preparations, no intact nucleic acid 
molecules of potential viral genome size have been identified. The virus would therefore need 
to be able to regenerate from small fragments. Additionally, the high correlation with PrP 
mutations in familial CJD would have to be explained. The virus should be rather common to 
account for almost 100% disease incidence in individuals carrying PrP mutations, and at the 
same time preferentially interact only with the mutant prion protein, in order to explain very 
low incidence of the disease in people lacking mutations in the Prnp gene (Chesebro, 2003). 
In spite of many efforts, no candidate viruses fulfilling all these criteria have been suggested. 
 The protein only hypothesis was first suggested by Griffith, who proposed that the 
infectious agent might be a self-replicating protein (Griffith, 1967). With the discovery of 
prion protein as the major component of scrapie, the altered pathogenic PrPSC has been 
proposed to be the sole component of the infectious agent (Bolton et al., 1982; Prusiner, 
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1982). However, this theory has not been proven as the purified in vivo PrP aggregates 
contain traces of nucleic acids, and only one study reported that transgenic mice infected with 
synthetic prions developed clinical symptoms following lengthy incubation periods (Legname 
et al., 2004). This result is however highly controversial as the mice used in the study were 
aging, and it has been shown that transgenic mice overexpressing PrPC spontaneously develop 
the disease at late stages of life without prion inoculation (Westaway et al., 1994). As other 
trials of producing an infectious prion in vitro have been unsuccessful (Hill et al., 1999), the 
infectivity of synthetic prions remains questionable. 
Two kinetic models for the conversion of PrPC to PrPSC have been proposed (Figure 
3-2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Mechanistic models for PrPSC formation.  
(a) PrPSC catalyzes the conversion of PrPC via a heterodimeric intermediate.  (b) 
PrPSC serves as a seed for aggregation of PrPC. Fragmentation of the polymer 
leads to multiplication of PrPSC seeds (adapted from(Caughey and Chesebro, 
1997). 
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In the first model (Prusiner, 1991), monomeric PrPSC forms a heterodimer with PrPC 
(Figure 3-2a). With the help of another protein (called “protein X”) PrPC is then converted to 
the infectious form and dissociates from the complex to auto catalyze the formation of more 
PrPSC molecules. The second model (Caughey et al., 1995) proposes that conversion of the 
cellular form to the scrapie form takes place upon recruitment of PrPC by an aggregate of 
PrPSC (Figure 3-2b). 
 Another alternative to the “protein only” prion hypothesis is a bacterial infection 
activating prion protein on the cell surface. Spiroplasma bacteria are able to resist high 
temperatures and irradiation and have been isolated from brains of sheep with scrapie, deer 
with chronic wasting disease and CJD patients (Bastian, 2005). Furthermore, the isolated 
Spiroplasma bacteria from sheep and deer were shown to cause TSE disease when inoculated 
intracranially into the animals (Bastian et al., 2007). However, no Spiroplasma rRNA has 
been found in scrapie-infected hamster brain (Alexeeva et al., 2006), therefore if presence of 
bacteria is not essential for development of the disease, it makes bacterial infection very 
unlikely to be the cause. 
  
3.1.3. The species barrier 
 One of the characteristic features of prion diseases is their transmissibility. In contrast 
to the relatively easy intra-species transmission, cross-species transmission of TSE, typically 
studied on laboratory rodents, is much less efficient as indicated by extended incubation times 
and incomplete spectrum of symptoms (Prusiner, 1996; Weissmann et al., 1996). This 
phenomenon, called the species barrier, can be overcome by a few passages in the new host, 
reflecting adaptation of the prion. Evidence exists that the adaptation depends on several 
factors, such as the pair of species involved and the direction of transmission. 
 The best example of the host related species barrier is the rabbit, which is resistant to 
prions from sheep scrapie, human CJD and BSE (Gibbs and Gajdusek, 1973). However, 
rabbits expressing ovine PrP gene, developed TSE upon infection with sheep scrapie 
(Sarradin, 2007). A similar observation was made in mice expressing mink and cervid PrP 
which made them susceptible to TME and CWD, respectively (Browning et al., 2004; Windl 
et al., 2005; LaFauci et al., 2006). 
 The dependence of species barrier upon the direction of trasmittion was well 
illustrated by experiments on recombinant C-terminally truncated mouse and hamster PrP 
(Vanik et al., 2004; Jones and Surewicz, 2005). The authors have shown that while 
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recombinant hamster PrP rapidly aggregates upon seeding with preformed hamster PrP fibrils, 
no polymerization is observed when hamster PrP is seeded with preformed mouse PrP fibrils 
(Figure 3-3a). In contrast, monomeric mouse PrP aggregates when seeded with either mouse 
or hamster PrP fibrils. However, the conformation of hamster-seeded mouse PrP fibrils is 
similar to those of pure hamster PrP, and the newly formed „2nd generation“ fibrils can be 
used to seed monomeric hamster PrP (Figure 3-3b). 
 
Figure 3-3. Cross species transmission modelled by seeded aggregation. 
(a) shPrP aggregates rapidly when seeded with preformed shPrP fibrils. Seeds of 
moPrP cannot convert monomeric shPrP. (b) Monomeric moPrP can be seeded 
both by mouse and hamster preformed fibrils. If seeded with shPrP, resulting 
fibrils have morphology similar to parent seeds and can be used to seed shPrP 
monomer (adapted from(Beringue et al., 2008). 
 
These results strongly suggest that the species barrier is encoded in the structure of 
PrPSC and that some types of fibrils can be used to seed the monomeric PrP of a different 
species because they are within the spectrum of allowed conformations. Still, these data were 
obtained on truncated forms of the proteins that lack the C-terminal glycosylation and the GPI 
anchor, and could not be reproduced with full length PrP (Makarava et al., 2007). Further 
studies are therefore needed to understand the cause underlying the species barrier. 
 
3.1.4. Prion protein 
 The cellular form of the prion protein (PrPC) is synthesized as a family of four 
members, which include the major subset of glycophosphatidylinositol (GPI) anchored 
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protein, two transmembrane forms of opposite topologies (NtmPrP and CtmPrP) and the minor 
soluble fraction (CytPrP) (Hegde et al., 1998; Holscher et al., 2001; Hegde and Rane, 2003). 
The prion protein is presented on the surface of neuronal cells (Kretzschmar et al., 1986) and 
through the interaction of the GPI-anchor with lipids associates with cholesterol- and 
glycosphingolipid-rich detergent resistant microdomains, called lipid rafts (Vey et al., 1996; 
Kaneko et al., 1997). 
 The structure of the prion protein comprises an unstructured N-terminal domain with 
five characteristic octapeptide repeats, and a globular C-terminus containing three helices, two 
short β-strands, a disulphide bridge and two glycosylation sites (Figure 3-4) (Zahn et al., 
2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Structure of the human prion protein. 
(a) Schematic overview of the primary sequence; the octarepeat region (yellow), 
α-helices (magenta), β-strands (blue), glycosylation sites (red) and the GPI anchor 
are indicated. (b) NMR structure of human prion protein fragment 121-230 (pdb 
entry 1QM0); structural elements are color coded as in a. 
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The hydrophobic helices 2 (residues 174-194) and 3 (200-228) are connected by a short loop 
and stabilized via a disulphide bridge between cysteins 179 and 214. Due to its polar amino 
acid sequence, helix 1 is not able to form hydrophobic interactions and is therefore isolated 
from the rest of the molecule (Morrissey and Shakhnovich, 1999) and thought to be stabilized 
by two arginine-aspartic acid salt bridges (Speare et al., 2003). 
 
3.1.5. Structural models of PrPSC 
 The abnormal form of PrPC, denoted PrPSC was found to be the major component of 
the infectious TSE agent (Prusiner, 1982). Studies of the two forms of the protein show 
several differences, which are summarized in Table 3-3. 
 
Table 3-3. Properties of normal and “scrapie” forms of the prion protein 
normal PrP (PrPC) abnormal PrP (PrPSC) 
function unclear TSE-specific 
GPI-anchored glycoprotein large aggregates and amyloid fibrils 
soluble insoluble in non-denaturing detergents 
mostly α-helical β-sheet enriched 
non-infectious major component of infectious prion agent 
proteinase K sensitive partially resistant to proteinase K 
 
PrPSC is insoluble in non-denaturing detergents, exists in an oligomeric or fibrillar 
form (Swietnicki et al., 2000) and shows partial resistance to digestion with proteinase K 
(Bolton et al., 1982). The molecule resulting from digestion of scrapie prions with proteinase 
K is termed PrP27-30 as in a SDS-PAGE gel it shows a band of 27-30 kDa. Many studies on 
in vivo isolated PrPSC are actually performed on PrP27-30, as the PrPSC preparations contain 
large amounts of PrPC. On a structural level PrP27-30 shows an increased β-sheet content of 
32-37 % and 12-17 % α-helix (Caughey et al., 1991; Gasset et al., 1993; Pan et al., 1993), in 
contrast to the predominantly helical PrPC (30 % helix and 4 % β-strand) (Zahn et al., 2000). 
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Several structural models of PrPSC that have been suggested so far (Figure 3-5) can be 
divided into two general categories: (i) structures in which helix 1 is converted to β-strand and 
(ii) structures in which helix 1 is retained. 
One of the first models (Figure 3-5a) was proposed by Cohen and coworkers (Huang 
et al., 1995), one year before the first solution NMR structure of mouse prion protein was 
determined (Riek et al., 1996). The model bases on various spectroscopic and genetic data and 
shows a four-stranded beta-sheet covered on one side with two helices. The β-sheet would be 
formed by extended β-strands S1 and S2 (see Figure 3-4) and helix 1 converted into two 
strands. In this arrangement, residues implicated in the species barrier are found on the 
solvent accessible face of the β-sheet. 
 A more recent model (Figure 3-5b) from the same group suggests a left-handed β-
helix as the structure of PrPSC (Govaerts et al., 2004). This model is based on electron 
crystallography projection maps of 2D crystals of mouse brain isolated PrP27-30. A 
simulation was performed for residues 89-175 of the mouse prion protein and the C-terminal 
helices were subsequently added to fit the EM images. In this model, helix 1 of the prion 
protein is also assumed to be converted to β-strand. 
 A model in which helix 1 is retained was proposed very recently as a result of a 
molecular dynamic simulation of human PrP90-230 at low pH (DeMarco and Daggett, 2007). In 
this model, all three helices are retained and formation of six short β-strands is suggested in 
the region between residues 90 and 166, two of which originate from strands S1 and S2 
present in PrPC (Figure 3-5c). 
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Figure 3-5. Structural models of PrPSC. 
(a) A four-stranded β-sheet is covered on one face with two helices; the four 
strands originate from β-strand 1 (red), β-strand 2 (blue), and converted helix 1 
(green) (Huang et al., 1995). (b) A left-handed β-helix arrangement (Govaerts et 
al., 2004). (c) Six β-strands are formed between residues 90 and 166 (DeMarco 
and Daggett, 2007). 
 
 
 
 
 
 
3. Human prion protein 
39  
3.2. Results 
3.2.1. Secondary structure analysis of human prion protein mutants 
 The various Prnp-gene mutants coding for fragments of the prion protein used in this 
study are schematically represented in Figure 3-6 (see also Table 2-1). Expression and 
purification of the encoded proteins was performed as described in 2.2.4 – 2.2.7, and included 
isolation of inclusion bodies, purification by affinity chromatography and refolding of the 
protein fragments.  
 
 
 
Figure 3-6. Schematic representation of the human prion protein stop mutants. 
 
A preliminary structural analysis by circular dichroism (CD) spectroscopy showed 
spectra characteristic for largely unstructured proteins (Watzlawik et al., 2006). 
Deconvolution of the CD spectra was inconclusive and reported presence of small amounts of 
both α-helical and β-sheet conformations in all of the mutant proteins (data not shown). 
Presence of secondary structure elements was detected by means of NMR secondary chemical 
shifts (SCS), which are defined as the differences between the observed chemical shift and the 
random coil chemical shift values. These small but distinct deviations are a very sensitive 
probe for secondary structure, especially in case of Cα and C’ atoms (Dyson and Wright, 
1998). A prerequisite for SCS analysis is the sequence specific assignment of resonances in an 
NMR spectrum. First, the backbone assignment of humPrP23-144 was obtained from standard 
three-dimensional NMR experiments (Table 2-3). The spectra of humPrP23-159 and humPrP23-
173 were then compared to that of the shorter mutant in order to identify resonances originating 
from the C-terminal extensions of the polypeptide chain, which were then assigned from 3D 
spectra (Figure 3-7). 
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Figure 3-7. Assignment of PrP stop mutants.  
(a) Overlay of 1H,15N-HSQC spectra of humPrP23-144 (black) and humPrP23-159 
(red). (b) Assignment of resonance peaks of residues 136-159. 
 
For the calculation of SCS, sequence corrected random coil values determined at pH 
3.0 were used (Schwarzinger et al., 2001), except for prolines and aspartates where the 
random coil values were taken from Wishart and Sykes (Wishart and Sykes, 1994). Averaged 
secondary chemical shifts of Cα and C’ atoms for humPrP23-159 are depicted in Figure 3-8. 
Stretches of positive values are indicative of propensity for α-helical conformation, which is 
clearly observed for residues 146-154. A comparison of the average SCS magnitude within 
the helix 1 region for humPrP23-159 and humPrP23-230 (based on BMRB entry 4402) reveals a 
helical content in the mutant of about 33 % with respect to the full length protein (data not 
shown). Interestingly, a propensity for extended structure is observed in the region 98-144 
which forms the proteinase K resistant core in PrPSC (Peretz et al., 1997). Although the prion 
protein mutants spontaneously aggregate in presence of phosphate at pH 6.5, no change in 
secondary structure preference was observed under low ionic strength conditions at this pH. 
 
 
 
 
 
3. Human prion protein 
41  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8. Secondary chemical shifts of humPrP23-159.  
SCSs were calculated as the difference between the observed chemical shift and 
the random coil values separately for C’ and Cα atoms and subsequently averaged 
to obtain ΔδC. Structural elements found in the full-length prion protein are 
indicated by open and filled bars. 
 
 Additional information about the structure and dynamics can be obtained from 
residual dipolar couplings (RDCs) which can be measured for proteins weakly aligned in 
liquid-crystalline media. RDCs have proven especially useful in detection of local structure in 
denatured and intrinsically unfolded states where measurements of global dimensions suggest 
a random-coil behavior (Tanford et al., 1966). Since the stop mutants of the prion protein are 
indeed largely disordered and the humPrP23-159 and humPrP23-173 show local structural 
propensities, a measurement of RDCs was performed to support the SCS analysis. An 
important factor that needs to be considered in RDC measurements is the surface charge of 
the liquid-crystalline medium used (Skora et al., 2006). To prevent electrostatic interactions 
between the alignment medium and charged residues in the helix 1 region, a nonionic nematic 
phase comprising a mixture of n-alkyl-poly(ethylene glycol) and n-alkyl alcohol (Ruckert and 
Otting, 2000) was used. The RDC profile of humPrP23-159 in C12E5 / n-hexanol is compared 
to the SCS data in Figure 3-9. A very good agreement is found within the helix 1 region and 
3. Human prion protein 
42  
the sign of RDCs for residues 23-50 and 90-135 reflects the structural tendencies observed 
with secondary chemical shifts. The inversion of the sign of residual dipolar couplings with 
respect to SCS seen for residues 135 and 139 suggests a change of the alignment tensor in this 
region. This might indicate that residues 135-143 align together with helix 1, however it 
should be noted that RDCs from only two residues in this region could be attained. Due to 
significant spectral overlap, no reliable RDCs could be obtained for the octarepeat region. 
 
Figure 3-9. 1H-15N dipolar couplings of humPrP23-159.  
(a) A comparison between secondary chemical shifts (black) and 1DNH dipolar 
couplings (blue) measured in presence of 5% C12E5/hexanol alignment medium. 
(b) Excerpts from the 1H,15N-IPAP-HSQC spectra showing isotropic (red) and 
anisotropic (blue) couplings for the four observable residues in the 134-142 
region. RDCs were calculated as differences between the isotropic and anisotropic 
couplings. 
 
 An interesting observation was made when comparing the chemical shifts between 
humPrP23-144 and humPrP23-159 spectra. Average shift differences were calculated according to 
Equation 3-1.  
( ) ( ) 22 5/NHAV δδδ +=Δ     (Eq. 3-1) 
As expected the extension of humPrP23-144 by the C-terminal helix 1 region results in changes 
in the chemical environment of residues 130–144 which is reflected by a shift of those 
resonances in the NMR spectrum. However, such behavior is also observed for the N-terminal 
residues 23-25, which suggest a possible long-range interaction of the helix 1 region with the 
N-terminus (Figure 3-10). Another possible explanation for this finding might be a change in 
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pH since the N-terminal residues are charged and an increased change in the chemical shift is 
seen for His111, however no such behavior is observed for histidines in the octarepeat region, 
which makes pH an unlikely cause of the chemical shift changes reported for residues 23-25. 
 
Figure 3-10. Long-range interaction between the N-terminus and the helix 1 
region. (a) Selected region of HSQC spectra showing shifts of resonances in the 
spectrum of humPrP23-159 (black) with respect to humPrP23-144 (red). (b) Averaged 
chemical shift differences between the spectra of humPrP23-144 and humPrP23-159 
calculated according to Eq.3-1. 
 
 
 In general, NMR investigations of secondary structure elements in mutants of the 
human prion protein confirmed the presence of helix 1 in the prion protein fragments 23-159 
and 23-173. Furthermore, an increased propensity for extended structure was observed in the 
region corresponding to the proteinase K resistant core in the fibrils, and a possible long-range 
interaction involving helix 1 and the N-terminal residues was identified. 
 
3.2.2. Aggregation and proteinase K digestion of amyloid fibrils of the prion protein 
 One of the advantages of using the stop mutants of the prion protein is that these 
fragments can be aggregated under physiologically relevant conditions (Kundu et al., 2003). 
The aggregation of these mutants was typically performed in a 50 mM potassium phosphate 
buffer at pH 6.5. However, under these conditions, the lag phase is significantly shortened and 
no difference in aggregation profiles of the prion protein variants was observed. The 
aggregation buffer was therefore changed to a 50 mM phosphate / acetate (1:1) solution and 
fibril formation was monitored by a standard Thioflavin T fluorescence assay. Surprisingly, 
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both in case of seeded and spontaneous aggregation, humPrP23-159 mutant was found to form 
fibrils faster than humPrP23-144, in a concentration independent fashion (Figure 3-11). Such 
behavior is surprising as the polar helix 1 segment consists in 50 % of charged residues and 
would therefore be expected to have a hindering effect on fibril formation. The finding that 
humPrP23-159 aggregates faster with respect to the variant lacking helix 1, suggests a 
promoting effect of this region on the aggregation of the human prion protein. Interestingly, 
the increased aggregation propensity of humPrP23-159 correlates with a case study of one 
patient carrying the Q160stop mutation (Finckh et al., 2000) who presented clinical symptoms 
six years earlier than patients carrying the Y145stop mutation (Ghetti et al., 1996). 
 
Figure 3-11. Aggregation of human prion protein stop mutants.  
Fibril formation by humPrP23-144 (filled triangles) and humPrP23-159 (open circles) 
was monitored by Thioflavin T fluorescence. The protein concentrations were: (a) 
340 μM, (b) 200 μM and (c) 80 μM. The assay was carried out by Dr. Jens 
Watzlawik. 
 
 Digestion of amyloid fibrils formed by humPrP23-144 and humPrP23-159 with proteinase 
K resulted in a release of a 7-8 kDa fragment (Figure 3-12a), consistent with previous 
biochemical observations (Salmona et al., 2003). Subsequently, a Western Blot analysis was 
performed (Figure 3-12b) using antibodies 1E4 and 6H4 directed against residues 98-109 and 
the helix 1 region, respectively. The 1E4 antibody recognized the presence of the target region 
in the soluble forms of the proteins as well as in the PK-resistant fragments of the both 
mutants. Recognition by the 6H4 antibody was positive only for the soluble form of 
humPrP23-159, which strongly suggests that the helix 1 region is not resistant to proteinase K 
digestion in amyloid fibrils of this prion protein fragment. 
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Figure 3-12. Helix 1 region is not resistant to digestion by proteinase K.  
(a) SDS-PAGE analysis of digestion products of humPrP23-144 and humPrP23-159 
amyloid fibrils. (b) Western Blot analysis with the 1E4 antibody detects 
proteinase K digested fibrils of both mutants, while the helix 1-targeted antibody 
6H4 regonizes only the monomeric form of humPrP23-159 demonstrating that the 
helix1 region is not resistant to proteinase K digestion. The epitope location for 
both antibodies is schematically depicted by black bars. SDS-PAGE and Western 
Blot analysis was performed by Dr. Jens Watzlawik. 
 
The proteinase K resistant fragments released from the fibrils of humPrP23-144 and humPrP23-
159 show a slightly different electrophoretic behavior suggesting either a N- or C-terminal 
extension of the PK-resistant fragment in humPrP23-159. Edman sequencing of the PK-resistant 
cores resulted in both cases in cleavage at residues 97-98 suggesting that the extension of the 
core of humPrP23-159 is C-terminal. However, considering the fact that the helix 1-targeted 
antibody 6H4 did not recognize the PK-resistant core of humPrP23-159 fibrils, and that the 
alternative SDS-PAGE system used here was shown to separate aggregation prone amyloid-β 
peptides differing in size by a single amino acid (Wiltfang et al., 2001), it is very likely that 
the C-terminal extension in humPrP23-159 proteinase K resistant core is only a few amino acids 
long and does not cover the entire helix 1 region. 
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 The size of amyloid aggregates of the prion protein variants was determined by 
diffusion based NMR experiments for the humPrP23-173 fragment. Because the signals 
originating from large assemblies such as amyloid fibrils are not observable in solution state 
NMR spectra, the diffusion measurement was performed under high-resolution magic angle 
spinning (see 1.2.2). Translational diffusion coefficient can be measured by spatial labeling of 
the molecules with a field gradient followed by a delay during which the molecules diffuse 
until their new position is decoded by another field gradient (Stejskal and Tanner, 1965). The 
resulting NMR signal is attenuated by the diffusion delay (Δ), and the length (δ) and strength 
(g) of the field gradients. If Δ and δ are kept constant during the measurement, a series of 1D 
spectra is acquired in which the signal attenuation depends solely on the strength of the 
applied field gradient. 
 
 
Figure 3-13. Molecular weight estimation of humPrP23-173 fibrils.  
(a) 1D proton spectra recorded without (blue) and with (red) magic angle 
spinning. (b) Signal intensity decays under pulsed field gradients recorded for 
humPrP23-173 fibrils (black), bovine serum albumin (green), 1,4-dioxane (blue) and 
water (red) measured using an LED pulse sequence. 
 
The diffusion coefficient of humPrP23-173 fibrils under HR-MAS (Figure 3-13a) was 
measured using a bipolar stimulated spin echo sequence (pulse program: ledbpgp2s, Bruker 
Biospin) as described in 2.4.4. The signal decay curves (Figure 3-13b) were fitted to a single 
exponential function and the experimental diffusion coefficient was calculated to be D = 3.3 x 
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10-11 m2/s. Because of the non-spherical shape of the aggregates, this value cannot be directly 
used to calculate the molecular weight based on comparison of the diffusion coefficient 
between the fibrils and the reference molecule. A recent study by Baldwin and coworkers 
reported that for large molecules rotational diffusion might contribute to the signal attenuation 
measured in the NMR experiment (Baldwin et al., 2007). Here however, a simple diffusion 
theory for an ellipsoid of revolution (Perrin, 1934) was applied, which accounts for both 
translational and rotational diffusion. The theory allows to calculate the corresponding 
diffusion coefficient for a spherical molecule of the same molecular weight, which 
considering the average dimensions of humPrP23-173 fibrils was found to be D0 = 6 x 10-11 
m2/s. Based on the Stokes-Einstein equation and using bovine serum albumin (BSA) as 
reference the molecular weight of the fibrils was determined to be in the range of 8 MDa 
which corresponds to ~600 monomeric units per fibril. 
 
3.2.3. NMR-detected H/D exchange studies of the prion protein mutants 
3.2.3.1. Optimization of experimental conditions 
 Due to the large size of amyloid fibrils, direct structural investigation of these 
assemblies is very challenging and experimentally difficult. However, the fibrils can be 
conveniently studied by H/D exchange experiments followed by dissociation of the 
aggregates and detection of solvent protection patterns in the monomeric state. A concept of 
such an experiment was introduced in 1.2.1. An important parameter that requires 
optimization in the quenched H/D exchange technique is the composition of the dissolving 
buffer, as the desolution of fibrils to monomer is fundamental for the success of the 
experiment. The ideal buffer should quickly and fully dissociate the fibrils and provide 
conditions under which exchange in the monomeric stage is slowed down. This is typically 
achieved by mixtures of dimethyl sulfoxide (DMSO) and dichloroacetate (DCA) (Hoshino et 
al., 2007). Several DMSO/DCA based solvents were tested, covering a concentration range of 
92-98% for DMSO and 0.01-0.5% for DCA, and a pH range of 4.0-6.5. While none of these 
solutions was found to fully dissociate the fibrils of prion protein stop mutants (Figure 3-
14b), a rapid and complete fibril dissolving was observed in 2 M guanidinium thiocyanate 
(GdnSCN) at pH 2.5 (Figure 3-14c). The GdnSCN buffer therefore fulfills all the 
requirements achieving fast and complete conversion of fibrils to monomers and slowing 
down the amide exchange rates due to the acidic pH of the solution. 
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Figure 3-14. Dissolution of amyloid fibrils of humPrP23-159.  
(a) Mature fibrils of humPrP23-159. (b) Commonly used mixtures of dimethyl 
sulfoxide (DMSO) and dichloroacetate (DCA) fail to fully dissolve humPrP23-159 
fibrils. (c) A complete and rapid dissolution is achieved in a 2 M solution of 
guanidinium thiocyanate at pH 2.5. The while scale bars indicate a size of 200 nm. 
 
3.2.3.2. Single residue detection of solvent protection in humPrP23-159 fibrils 
 Fibrils of humPrP23-159 (Figure 3-14a) were prepared as described in 2.2.8 and 
exchanged with 0.4 % formic acid in D2O, pD 2.5. Fibrils were dissolved in 2 M GdnSCN in 
50% H2O / 50% D2O and a series of 1H,15N correlation spectra were recorded at 278 K as 
outlined in 2.4.5. Figure 3-15 shows a selected region of the 1H,15N-HSQC spectra taken at 1 
h, 6 h, and 24 h after the dissolution of fibrils. Due to the experimental setup used, if a residue 
is solvent accessible in the fibrillar form of the protein the amide proton will exchange with 
the solvent to deuterium and in the first spectrum no signal is observed. As the back-exchange 
in monomeric state is not absolutely quenched, over time the deuteron will experience partial 
back-exchange to proton, which in the NMR spectrum results in increase of signal intensity. 
This is the case for R25 and K104. 
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Figure 3-15. NMR-based detection of H/D exchange.  
The panels show selected regions of a 1H,15N-HSQC spectrum after (a) 1, (b) 6, 
and (c) 24 hours after the dissolution of fibrils.  
 
A residue that is buried in the fibril core shows an opposite behavior in the H/D exchange 
experiment. As it is protected from solvent in the fibrillar state the amide group remains 
protonated during the exchange period and after dissolving yields a signal in the NMR 
spectrum. During the back-exchange process the signal will slowly decay as the proton 
partially exchanges to a deuteron as seen for V122 and I139. 
 By plotting the relative signal intensities at the end of the back-exchange period 
against the sequence, a solvent protection map is obtained. Figure 3-16 shows a protection 
map for humPrP23-159 fibrils after 3 days of deuterium exchange. As expected, the N-terminal 
part of the protein covering residues 23-97 remains unstructured in the fibril and is therefore 
not protected from the solvent, which is represented by relative intensity ratios above 1 (less 
than 50% protection). Interestingly, regions with different protection are observed within the 
proteinase K resistant region 98-144. The highest protection levels are seen for amino acids 
121-139. Residues 111-120 are clearly less buried in the core and therefore experience lower 
solvent protection, while the region 98-110 shows similar solvent accessibility as the N-
terminal part of the protein. Most importantly, helix 1 residues 147-157 show very high 
relative intensity ratios indicative of very low protection from solvent in the amyloid fibrils. 
This is in full agreement with the proteinase K digestion experiment confirming that helix 1 is 
not converted to β-sheet and does not contribute to the proteinase K resistant core of the prion 
protein fibrils. In fact, the very low protection factors may suggest that this segment is fully 
flexible in the fibril. 
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Figure 3-16. Protection map of humPrP23-159 fibrils after 3 days of H/D exchange. 
Positions of octarepeats (R1-R4), β-strand 1 (S1) and helix 1 (H1) are indicated 
by open bars; the hatched bar marks the proteinase K resistant core in humPrP 
fibrils. 
 
 Additional information on the rigidity of various segments of humPrP23-159 within the 
amyloid fibril structure can be obtained by comparing the H/D exchange profiles after 
different exchange times. Longer incubation of fibrils with D2O results in saturation of H/D 
exchange in the flexible regions and further incorporation of deuterium in the rigid parts. 
Figure 3-17 shows a comparison between H/D exchange profiles of humPrP23-159 fibrils 
obtained after a 3- and 7-day exchange with D2O.  
 
Figure 3-17. Time dependence of deuterium incorporation into humPrP23-159 
fibrils. The overlay of protection maps recorded after 3 days (blue) and 7 days 
(red) reveals two fragments with slower deuterium incorporation encompassing 
residues 111-116 and 133-139. 
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In the previously identified solvent accessible regions of the protein (residues 23-110 
and 141-159), the exchange process is saturated after 3 days. Within the amino acids 110-140 
two regions (111-116 and 133-139) are showing a significant change in deuterium 
incorporation between the 3- and 7-day time points. 
Taken together, the collected H/D exchange data suggest at this stage that the core of 
the humPrP23-159 consists of three regions with distinct solvent protection. The first would be 
located around residues 111-118 and to account for the observed level of deuterium 
incorporation, it would need to be located on the outside of the core. The other two regions 
would comprise residues 121-127 and 129-139 with the latter being the one most buried in the 
rigid core of the fibrils. A potential turn at residues 119-120 can also be concluded, and this 
hypothesis is further supported by the analysis of signal intensity changes during the back-
exchange process for individual residues (Figure 3-18). 
Out of a total of 31 residues in the H/D exchange-mapped fibril core, 24 signals could 
be unambiguously assigned in the 1H,15N-HSQC spectra. Out of the 6 missing residues, one is 
a proline (Pro137) and the remaining five (M112, G123, G127, Y128, G131 and I138) were 
overlapping with other signals. Among all residues in the 111-141 region, G119 and A120 
show the most pronounced increase in signal intensity after the dissolution of fibrils, which 
indicates that these two amino acids exhibit higher amide proton exchange with the solvent 
than the neighboring residues. The change in signal intensity over time for V121 shows a 
striking difference with respect to A120 and clearly indicates that the second proposed core 
region starts exactly at this residue. 
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Figure 3-18. Residue specific H/D exchange profiles for residues 111-141. 
Changes in signal intensity during the back-exchange process were followed by a 
series of 1H,15N-HSQC experiments providing data with single residue resolution. 
 
3.2.3.3. Fibrils of different stop mutants of the human prion protein show similar 
solvent protection 
The observations made for fibrils of humPrP23-159 are also seen in the longer fragment – 
humPrP23-173, which spans the β-sheet 2 region of the prion protein. The comparison of 
solvent protection patterns for the two mutants after 7 days of exchange is depicted in Figure 
3-19. A remarkably good agreement between the relative intensities at the end of the back-
exchange process is seen in all the regions of the two proteins. 
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Figure 3-19. Fibrils of different humPrP stop mutants share common structural 
features. An overlay of protection maps of humPrP23-159 (red) and humPrP23-
173 (blue) fibrils exchanged with D2O for 7 days shows a very good agreement 
throughout the entire sequence. 
 
3.2.4. Structural models of the core of human prion protein fibrils 
 The H/D exchange profiles of human PrP mutants studied here consistently indicate 
the presence of a small fibril core comprising residues ~111-139. In order to suggest a 
structural model of this core, the CS-Rosetta package was used (Shen et al., 2008; Shen et al., 
2009). The input chemical shift information required by CS-Rosetta was taken from a recent 
solid state NMR study on fibrils of humPrP23-144 (Helmus et al., 2008). Helmus and coworkers 
report that in measurements above -20oC only signals from residues 112-140 are observable 
which is line with our findings and justifies the use of chemical shift information provided by 
the authors. 
 
3.2.4.1. MFR mode 
The CS-Rosetta run was performed as described in 2.4.6 to generate 200 candidates for 3-
residue and 9-residue fragments using the molecular fragment replacement (MFR) search 
protocol. The so-called “flight maps” showing the Φ / Ψ angles of the 10 best 9-residue 
fragment candidates (Figure 3-20) were generated using the scrollRama.tcl script of the 
NMRPipe system (Delaglio et al., 1995).  
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Figure 3-20. Flight maps for the 10 best 9-residue fragment candidates.  
Φ / Ψ trajectories are plotted onto Ramachandran maps with possible 
conformations of the polypeptide chain marked in grey; orange boxes indicate the 
average Φ / Ψ value ± one standard deviation. 
 
For residues 129–140, the Φ / Ψ angles of all 10 fragments fall into the β-strand region of the 
Ramachandran plot. Higher structural diversity is observed for the glycine rich region 123-
127, however also here a general tendency for β-strand is clearly visible. Interestingly, an 
evident turn is predicted around Gly119 and Ala120, which is in very good agreement with 
the H/D exchange data. Considering that the input chemical shifts were obtained for fibrils of 
humPrP23-144, this finding further supports the idea that fibrils of different stop mutants of the 
human prion protein share common structural features. 
 To prevent occurrence of end effects, a “triplicate” fragment was generated in which 
the three monomeric segments comprising residues 113-140 are connected by a 20-residue 
flexible linker consisting of Gly-Ser repeats, with the final sequence: 
(M112-F141)-(GS)5-(M112-F141)-(GS)5-(M112-F141).  
For the linker region random coil chemical shift values of Gly and Ser (Wishart et al., 1995) 
were used to complete the CS-Rosetta input table. Figure 3-21 shows the flight maps of the 
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central monomer together with the preceding 3 and proceeding 2 residues of the linker. As 
expected, no significant changes are seen in the core region with respect to the previous 
prediction (see Figure 3-20). The N-terminal extension by as little as two additional residues 
of the linker, more clearly shows the formation of a β-strand including residues 112-115 and 
the Ser-Gly pair of the linker. This suggests the first strand of the humPrP23-159 fibril core to 
encompass residues 111-115. On the other hand, no such effect is observed for the C-terminal 
linker extension, where the predicted core ends clearly at His140.   
Figure 3-21. Flight map of the 10 best 9-residue fragments for the “triplicated” 
peptide. 
 
3.2.4.2. Hybrid mode 
The hybrid mode of CS-Rosetta is an alternative approach to the MFR fragment 
search, and is recommended in case of incomplete/imperfect input chemical shift assignments 
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(Shen et al., 2009). For the “hybrid” fragment search the same input chemical shift table was 
used as in the MFR fragment selection. After the fragment selection was completed, the 
resulting fragments were sorted according to the CS-Rosetta scores and fragments with a CS-
score larger than 2.5 were discarded. The flight maps for the remaining best scoring fragments 
are shown in Figure 3-22. 
Figure 3-22. Flight maps of the best 9-residue fragments selected with the hybrid 
approach. 
 
 An overall agreement is found between the flight maps of the best fragments selected 
with the MFR (Figure 3-20) and hybrid (Figure 3-22) modes, however the trajectories 
obtained with the hybrid approach tend to vary more and cover a larger area of the 
Ramachandran space. This is the case for residues 116-119, 123-127, and 130-135. 
 Inspection of the 9-residue fragments containing the Gly-rich region 123-127 
identified two of the best 10 fragments centered around Leu125 to have both low chemical 
shift score and very high sequence similarity to the target sequence (VVGGLGGYM). Both 
fragments were found to contain the GGXGG motif, and one of the fragments contained 
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additionally a hydrophobic and an aromatic residue at positions 125 and 128, respectively. 
These two fragments originated from pdb files 1xez and 2hah (Figure 3-23a,b). In both of the 
corresponding proteins the Gly-rich motifs are forming loops within β-sheets (Figure 3-
23c,d), which further supports the hypothesis that residues 123-127 form a loop between two 
β-strands in the core of humPrP fibrils. 
 
Figure 3-23. Structures of Gly-rich regions in fragments selected by CS-Rosetta. 
(a) Structure of the Vibrio Cholerae Cytolysin pro-toxin (pdb entry 1xez) and (c) 
the 9-residue fragment between residues 631-639 selected by CS-Rosetta. (b) 
Structure of the FIV 12S protease (pdb entry 2hah) and (d) the 9-residue fragment 
between residues 55-63 selected by CS-Rosetta. (a,c) The selected 9-residue 
fragments are highlighted in red; (b,d) atom colors are: C (black), N (blue), O 
(red), S (yellow), H atoms are not shown. 
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3.3. Discussion 
Transmissible spongiform encephalopathies are a group of diseases in humans and 
animals, caused by conversion of the cellular prion protein to it’s pathogenic “scrapie” form 
and aggregation thereof. In this work the aggregation properties and fibrillar structure of the 
human prion protein was studied based on two stop mutants - humPrP23-144 and humPrP23-159. 
Importantly, both of these construct are disease related causing a Gerstmann-Sträussler-
Scheinker-like phenotype (Ghetti et al., 1996; Finckh et al., 2000) and were found to 
aggregate in vitro under non-denaturing conditions (Kundu et al., 2003; Watzlawik et al., 
2006). 
The following paragraphs discuss the novel experimental data and their importance for 
understanding the mechanism of the prion diseases. Implications for prion protein 
polymorphism and the species barrier are presented, and finally the recently proposed 
structural models of PrPSC are discussed in the light of our findings. 
 
3.3.1. The role of helix 1 in the aggregation of human prion protein 
 Conversion of PrPC to it’s pathogenic form PrPSC results in significantly increased β-
sheet content in the latter (see 3.1.5). As helices 2 and 3 are stabilized by a disulfide bridge, it 
was postulated that conversion of the charged and structurally isolated helix 1 into β-strand is 
the starting point in formation of PrPSC (Huang et al., 1995). Here, by using two naturally 
occurring stop mutants of the human prion protein – humPrP23-144 and humPrP23-159 – it was 
shown that helix 1 is not resistant to digestion with proteinase K in the fibrillar form of 
humPrP23-159 (Figure 3-12). Supported by the solvent accessibility of this region in the 
fibrillar form of PrP (Figure 3-16), this provides strong evidence that the helix 1 region is not 
converted to β-strand upon aggregation of the prion protein.  
Furthermore, humPrP23-159 was found to aggregate faster than humPrP23-144 in a 
concentration independent fashion (Figure 3-11). This is rather surprising as helix 1 contains 
charged residues, which would normally be expected to increase the solubility and hinder 
aggregation. The faster fibril formation of humPrP23-159 strongly suggests involvement of 
helix 1 in the aggregation mechanism, however the nature of this aggregation-promoting 
effect is unknown. One possible explanation is formation of intermolecular salt bridges 
(Morrissey and Shakhnovich, 1999) by aspartates and arginines within the helix 1 region. An 
alternative mechanism would involve an interaction between the N-terminus and the helix 1 
region, resulting in stabilization of the aggregates. Such an interaction could be concluded 
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from the NMR-data presented in Figure 3-10 and was previously suggested by Watanabe and 
coworkers based on results of a cysteine-scanning spin-labeling experiment (Watanabe et al., 
2006). 
 Interestingly, faster aggregation of humPrP23-159 with respect to humPrP23-144 correlates 
with a clinical report of a patient carrying the Q160stop mutation (Finckh et al., 2000), who 
developed symptoms six years earlier than patients carrying the Y145stop mutation (Ghetti et 
al., 1996). 
 
3.3.2. Evaluation of structural models of PrPSC 
 The experimental data presented in this work have several consequences for the 
possible architecture of fibrils of human prion protein, and by providing structural restrains 
can be used to evaluate the existing structural models of PrPSC. 
 Firstly, using two independent approaches we have provided strong evidence that helix 
1 region is not converted to β-strand upon aggregation of humPrP. The biochemical assay 
utilizing limited proteolysis showed that helix 1 does not contribute to the proteinase K 
resistant region in the humPrP23-159 fragment. This was confirmed by hydrogen/deuterium 
exchange measurement revealing solvent exposure of helix 1 region in amyloid fibrils of stop 
mutants of humPrP. Furthermore, the region corresponding to β-strand 2 in the monomeric 
protein was also found to be solvent accessible as evidenced by the exchange pattern of 
humPrP23-173. Even though helix 1 does not contribute to the β-sheet core of the fibrils, it was 
found to have a promoting effect on aggregation of humPrP. 
 Secondly, a combination of H/D exchange data and the CS-Rosetta predictions leads 
to the conclusion that the rigid core of amyloid fibrils of human prion protein stop mutants 
consists of four β-strands (residues 111-115, 120-122(-123), (127-)128-135 and 137-140) 
with the first strand being the least- and the last being the most-solvent protected. 
 Even though the GSS-related prion protein constructs used in this study did not 
contain the C-terminal helices 2 and 3, evidence exists that these segments are buried in the 
fibrils (Lu et al., 2007), however are not converted to β-strands during the aggregation process 
(Wille et al., 2002; Govaerts et al., 2004). A conversion of these regions to β-strands would be 
unlikely due to the presence of the disulfide bridge stabilizing the two helices and it was 
shown that no formation of intermolecular disulfide bonds occurs in multimeric assemblies of 
the prion protein (Welker et al., 2002). Furthermore, the involvement of helices 2 and 3 in 
formation of PrPSC was suggested in neuroblastoma cells, where truncated variants of the 
3. Human prion protein 
60  
prion protein lacking helices 2 or 3 were much less resistant to digestion with proteinase K 
than full length PrPSC (Muramoto et al., 1996). 
Taken together, none of the PrPSC models shown in section 3.1.5 fully accounts for all 
the experimental data: 
(i) The model assuming a four stranded β-sheet covered with helices 2 and 3 (Huang et al., 
1995), assumes conversion of helix 1 into a β-strand (see Figure 3-5a) and therefore does not 
comply to our experimental findings, 
(ii) The model of Govaerts and coworkers (see Figure 3-5b) suggests a β-helical arrangement 
in the region between residues 89-175 (Govaerts et al., 2004). Even though the positions of 
individual β-strands do not fit the data presented here, this model cannot be excluded as it has 
been suggested based on 2D crystals of the prion protein, which might be morphologically 
distinct from amyloid fibrils but are found in preparations of PrP23-30 together with amyloid 
fibrils (Wille et al., 2002), 
(iii) The MD simulation by DeMarco and Daggett of humPrP90-230 at acidic pH (Figure 3-5c) 
leads to six β-strands in the region 90-166 (E1: 90-95, E2: 99-102, E3: 119-121, E4: 126-134, 
E5: 137-139 and E6: 160-165). Although the positions of strands E4 and E5 fit very well to 
our experimental data, no evidence was found for the formation of strands in regions E1, E2 
and E6 of the MD simulation. Furthermore, the position of strand E3 is in disagreement with 
the turn observed at Gly119, 
(iv) Another MD-based model was proposed based on a simulation of conversion of Syrian 
hamster PrP(109-219) with D147N mutation at low pH (DeMarco and Daggett, 2004). 
Similarly to the other model suggested by the same authors, helix 1 is not converted into a β-
strand and is considered to exist in PrPSC, which is in agreement with the proteinase K 
digestion experiment, however the H/D exchange data strongly suggest that helix 1 region is 
unstructured in the fibrils of humPrP. Helices 2 and 3 are significantly shortened, matching 
the decreased α-helical content in PrPSC with respect to PrPC (see Table 3-3). Presence of 
four β-strands is predicted in the core of the fibrils at positions 116-119, 129-131, 135-140 
and 161-163. While the first three strands match relatively well the CS-Rosetta prediction, no 
evidence is found for the formation of a β-strand encompassing residues 161-163, similarly to 
the other MD-based model. 
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3.3.3. Core of amyloid fibrils of human prion protein stop mutants 
 A recent study by Lu and coworkers (Lu et al., 2007) utilized hydrogen / deuterium 
exchange and detection by mass spectrometry to map the fibrillar core of the 90-230 fragment 
of the human prion protein. The authors report the highly protected fibrillar core to be located 
in the C-terminal part in regions corresponding to α-helix 2, major part of helix 3, and the 
loop between these two helices. No significant protection was detected in the N-terminal part 
of the used construct (residues 90-130), however this conclusion was drawn based only on 
two peptic fragments of 32 and 40 residues. The analysis of such strikingly long fragments is 
prone to oversimplification and presence of short, highly protected regions cannot be 
excluded. It is also unexpected that the proteinase K resistant region situated between residues 
98 and 144 would be solvent exposed in the fibrils.  
Another investigation of mass spectrometry-detected hydrogen / deuterium exchange 
in fibrils of full length mouse PrP concluded presence of two highly protected regions 
comprising residues 24-98 and 182-212, while residues 99-181 were found to be more solvent 
exposed, but less than in the monomeric protein (Nazabal et al., 2009). The high protection of 
the N-terminal region and lower protection of residues 99-181 is not only contradicting our 
data but also basic biochemical proteinase K digestion assays, which show that the N-terminal 
residues 23-90 are highly susceptible to proteolytic cleavage in PrPSC (Kocisko et al., 1996). 
 To examine in detail the solvent protection of humPrP fibrils we have used H/D 
exchange in combination with detection by NMR, which (in contrast to mass spectroscopy) 
offers single residue resolution. Our data indicate clearly that the rigid, and highly solvent 
protected core of humPrP23-159 fibrils comprises residues 111-139 (Figure 3-16). A detailed 
analysis of protection maps obtained after varying the exchange time suggests presence of 
three regions with different solvent protection levels – 111-118, 121-127, and 129-139 
(Figure 3-17). 
An NMR-detected H/D exchange study of mature fibrils formed by mouse PrP 
fragment 106-126 (corresponding to residues 107-127 of the human prion protein) reports 
high protection for residues 110-119 (111-120 in humPrP), confirmed by a MD simulation 
predicting β-sheet conformation in this region (Kuwata et al., 2003). Comparison with our 
data reveals that fibrils of the 106-126 fragment and of humPrP23-159 have different cores, and 
indicates that the region investigated in the two peptide studies comprises only a part of the 
core of PrP fibrils. Furthermore, the aggregation of mouse PrP(106-126) was performed under 
non-physiological conditions in presence of 50 % acetonitrile. 
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A very recent publication by Walsh and coworkers explores the structure of amyloid 
fibrils formed by a peptide encompassing residues 106-126 of the human prion protein (Walsh 
et al., 2009). The authors report an extended β-strand conformation between residues 113 and 
126. As a proof of principle, we have performed a CS-Rosetta fragment search using the 
chemical shift data reported by the authors (Figure 3-24). Indeed, in agreement with the 
published data, a fully extended structure is predicted for region 113-126. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-24. Flight map of the best 10 fragments assembled for residues 113-126 
of the amyloid forming peptide 106-126. CS-Rosetta prediction was run only on 
residues 113-126, as the chemical shifts for residues 106-112 were not reported 
(Walsh et al., 2009). 
 
 Our observation that the fibrillar core of humPrP23-159 and humPrP23-173 is located 
around residues 111-139 is in agreement with a solid-state NMR study on humPrP23-144 by 
Helmus and coworkers (Helmus et al., 2008). The authors report that in measurements above  
-20 oC only signals from residues 112-140 are observable, and based on a simplified chemical 
shift-based structure prediction conclude the presence of 3 strands in the core of the fibrils 
(residues 112-115, 118-122 and 130-139). However, the PSSI algorithm used by Helmus and 
coworkers tends to be unreliable for Gly residues, and the results of the PSSI prediction are in 
disagreement with our H/D exchange data. The chemical shift information provided by the 
authors was therefore used in an attempt to predict the structure of the fibrillar core using the 
CS-Rosetta package (Shen et al., 2008; Shen et al., 2009). The results of the CS-Rosetta runs 
(Figures 3-20 to 3-22) suggest a presence of four β-strands within the core of the fibrils. 
These are located in regions 111-115, 120-122(-123), (127-)128-135 and 137-140. 
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Furthermore, in agreement with results of the H/D exchange experiment, a turn was found at 
Gly119. 
The experimental data presented here and the expected structure in the C-terminal 
region of the human prion protein (see 3.3.2) are summarized in Figure 3-25. 
 
Figure 3-25. Structural architecture of humPrP fibrils. 
(a) Schematic representation of structural differences between PrPC and PrPSC; 
H1,H2,H3 – helices 1, 2 and 3; S1,S2 – β-strands 1 and 2; the expected structure 
of the C-terminal region of the fibrillar form (magenta) was concluded from data 
available in literature (see 3.3.2). (b) The core of amyloid fibrils of humPrP stop 
mutants. NMR-detected H/D exchange reveals presence of three regions with 
protection levels increasing towards the C-terminus (I24h/I0 values are: 0.5-0.75 
(red), 0.75-1.0 (orange), 1.0-1.25 (yellow), >1.25 (white), unknown (grey)) and a 
turn at Gly119-Ala120. Presence of four β-strands is predicted by CS-Rosetta 
based on chemical shift data from a solid-state NMR study on fibrils of humPrP23-
144 (Helmus et al 2008); a turn at Gly119 is also found in the chemical shift 
prediction. Regions of importance for pathology of the disease are indicated in 
green and blue; the Gly-rich region is marked in pink. 
 
3.3.4. Implications for prion protein polymorphism and the species barrier 
The most prominent hallmarks of transmissible spongiform encephalopathy pathology 
are the existence of prion strains and the so-called “species barrier” (see 3.1.3.).  
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The highest sequence homology to human prion protein is found in the hamster, with 
only 18 residues differing between the two proteins and one insertion at position 206 in the 
hamster PrP. Interestingly, only two amino acid substitutions are found in the region 111-139 
forming the core of the humPrP23-159 fibrils. These are Ile138 and Ile139, which are both 
replaced by methionines in the hamster variant of the protein. In NMR spectra, the signal of 
Ile138 is overlapping with another resonance, while Ile139 is very well separated and can be 
reliably studied. According to both the H/D exchange data and CS-Rosetta predictions, both 
isoleucines are found in a β-strand in the most protected region in the amyloid fibril core (see 
Figure 3-25). Strikingly, Ile139 also showed the highest solvent protection over the entire 
length of the studied fragment (Figure 3-16). It was also shown that especially the amino acid 
alterations I138M and I139M are responsible for the sequence-based barrier preventing cross-
seeding of human and hamster prion proteins (Vanik et al., 2004). These observations 
highlight the importance of positions 138 and 139 for the species barrier and indicate that 
replacement of isoleucines with methionines could change the fibrillar core and that the 
species barrier might be therefore related to the fibril architecture. In fact, evidence exists that 
differences in fibril morphology are a result of changes in the excited states of the proteins 
(Kremer et al., 2007).  
The second factor determining the pathology of prion diseases is the polymorphism at 
position 129. The human Prnp gene exists as two alleles encoding either methionine or valine 
at codon 129 (Owen et al., 1990). The frequency of the evolutionary primitive (found in other 
mammals) Met129 allele is ~0.7, resulting in more than 40 % frequency of heterozygotes 
(reviewed in(Mitrova et al., 2005). The polymorphism affects both susceptibility to disease 
and the onset of clinical symptoms (Collinge et al., 1991; Palmer et al., 1991; Brown et al., 
1994; MacDonald et al., 1996; Kovacs et al., 2000). In fact, the course of the disease can be 
altered to such extent that it leads to a different phenotype. The D178N mutation causes fatal 
familial insomnia when codon 129 encodes Met, however if a Val residue is present at 
position 129 the D178N mutation leads to dementia and classifies as familial Creutzfeldt-
Jakob disease (Goldfarb et al., 1992). Interestingly, an effect of M/V129 polymorphism was 
reported also for the humPrP23-159 fragment causing a GSS-like phenotype. A case study of 
two brothers carrying the Q160stop mutation revealed an earlier onset and a severe and 
rapidly progressing course in the patient homozygotous for M129, while the other one was 
heterozygotous and his disease had a mild course (Finckh et al., 2000). In our study of 
humPrP23-159, Met129 (similarly to Ile138 and Ile139) was found to be highly protected from 
solvent exchange (Figure 3-16). The presence of Met129 in a β-strand at the edge of the 
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deeply buried region in the core of the fibrils suggests that replacement of this residue with a 
valine might cause changes in the kinetics of aggregation as well as in the structure of the 
core.  
The deuterium incorporation curves of residues 129 and 139 are in agreement with the 
logical expectation that sites responsible for different aggregation behavior and resulting 
disease pathology should occur in regions strategic for fibril architecture. 
 
3.3.5. Conclusions and outlook 
 Summarizing the data presented here (Figures 3-12 and 3-25) and reported in the 
literature (see 3.3.2), we propose the following model for amyloid fibrils of the human prion 
protein. The core of the fibrils contains four hydrogen-bonded β-strands (111-115, 120-123, 
127-135 and 137-140) with possible turns around Gly119 and the GGXGG motif (123-127), 
and two disulfide-bridged helices originating from helix 2 and helix 3 segments. Considering 
lack of structure in the helix 1 region and the decreased α-helical content in PrPSC with 
respect to PrPC, both helices would need to be shorter than in the monomeric protein, however 
not converted into β-strands. High solvent protection of these two regions could be explained 
by intra-helical hydrogen bonding or packing on the interface of the β-sheet core. The N-
terminal residues 23-98, as well as regions corresponding to helix 1 and β-strand 2 are 
proposed to be largely unstructured and solvent accessible on the outer surface of the fibrils. 
 Useful information for determination of the structure of humPrP fibrils can be 
obtained from subsequent solid-state NMR studies. 
 Further research plans include a combined study on amyloid fibrils of the full length 
human prion protein utilizing the NMR-detected H/D exchange experiment and the high-
resolution magic angle spinning (HR-MAS) technique, in order to investigate the presence of 
helices 2 and 3 in the fibrils of humPrP, and solvent protection of the C-terminal region. 
Furthermore, the structural differences underlying the species barrier will be explored by 
comparing solvent protection maps of human and Syrian hamster PrP.  
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4. Human beta-2-microglobulin 
4.1. Introduction 
4.1.1. β-2-microglobulin and dialysis-related amyloidosis 
 The rising incidence of protein misfolding diseases in recent times may be associated 
with increasing life expectancy in many parts of the world and several other risk factors such 
as obesity, which often reaches a scale unrecorded in the human history (Csermely, 2001). In 
that sense, these diseases may be thought of as lifestyle related or even human-caused. A 
particular example of a disease related to human activity is dialysis-related amyloidosis, 
which is caused by long-term hemodialysis used to treat kidney failure. In this unfortunate 
case, a medical procedure meant to improve the status of people with chronic renal failure 
leads to an inevitable onset of another disorder. DRA is characterized by pain and decreasing 
mobility resulting from deposition of amyloid aggregates in skeletal tissue (Casey et al., 
1986). These deposits (Figure 4-1) contain fibrils of β-2-microglobulin (hβ2m) (Gejyo et al., 
1985), which is the light chain of the major histocompatibility complex I (MHC-I) and as 
such it is presented on the surface of every cell in the body displaying MHC-I.  
 
Figure 4-1. Aggregation of β-2-microglobulin causes dialysis-related 
amyloidosis. (a) Structure of native hβ2m (pdb entry 1LDS); the disulfide bridge 
between C25 and C80 is marked in orange. (b) A negatively stained TEM image 
of ex-vivo fibrils of hβ2m (adapted from Jahn et al., 2008). (c) Scintigraphy image 
of amyloid deposits in DRA patients (adapted from(Linke et al., 2000). 
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The protein is regularly released in a process of turnover (Floege and Ehlerding, 1996) and 
degraded in the kidney. In healthy individuals, hβ2m reaches a plasma concentration of 1-3 
mg/L, however in case of kidney failure and subsequent long term treatment by dialysis the 
concentration rises more than 10-fold as the current procedures are not able to properly 
remove β-2-microglobulin from the organism (Ohashi, 2001). Accumulation of the protein 
leads to self-association presumably as a result of spontaneous population of less folded states 
or interaction with copper ions originating from the dialysis membrane. 
  β-2-microglobulin is 99 residues long (MW of 11.8kDa) and natively has a seven-
stranded β-sandwich fold with strands A, B, D and E forming one β-sheet, and strands C, F 
and G forming the other (Figure 4-1a). The two sheets are stabilized by a disulfide bridge 
between Cys25 and Cys80 in strands B and F, respectively (Becker and Reeke, 1985; Madden 
et al., 1993). 
 
4.1.2. Folding, unfolding and aggregation of hβ2m 
 Folding of β-2-microglobulin is a two stage process, in which the second very slow 
kinetic phase involves a trans-cis isomerization of the highly conserved Pro32 (Jahn et al., 
2006). Refolding experiments on a P32G mutant of hβ2m showed that this variant folds 
without the slow phase. A crystallographic study of a closely related P32A mutant revealed 
that the proline isomerization step imposes further structural rearrangements leading to 
removal of a β-bulge in edge strand D and dimerization of the mutant protein (Eakin et al., 
2006). The β-bulge is present when hβ2m is bound to the MHC-I complex (Trinh et al., 2002) 
and it is postulated to prevent the protein from edge-to-edge aggregation (Richardson and 
Richardson, 2002).  
It has been shown that high concentration of hβ2m alone are insufficient to cause 
aggregation and that the amyloid fibril formation requires a partial unfolding of the protein 
(Figure 4-2) (Chiti et al., 2001). This can be achieved in vitro by copper binding (Morgan et 
al., 2001), addition of non-esterified fatty acids (Hasegawa et al., 2008) or acid denaturation. 
In the latter case, the highest population of the partially unfolded intermediate occurs at pH 
3.6, where also the rate of fibril formation reaches a maximum (McParland et al., 2000). 
Conformational heterogeneity leads to only 28 signals being observable under these 
conditions. A denaturant titration experiment allowed for identification of 4 groups of 
residues depending on their denaturation profile (McParland et al., 2002). The study reports 
that residues in the N-terminal region including β-strand A unfold already at low 
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concentrations of urea, followed by the C-terminal strand G. Strands C and D become 
denatured at 1.5 M urea. At an urea concentration of 3 M only parts of strands B and F and 
strand E remain structured and further denaturation leads to 63 resonances observable in 
presence of 9 M urea. This suggests that dissociation of the N- and C-terminal strands may be 
sufficient to initiate aggregation of the protein, however the applicability of these findings to 
elucidation of the disease mechanism is questionable, as the aggregates formed at pH 3.6 have 
a form of thin and flexible filaments (McParland et al., 2000) and are therefore 
morphologically distinct from in vivo amyloid fibrils. The optimal conditions for in vitro 
formation of hβ2m fibrils were found at pH 2.5, where the protein is largely unstructured 
(Naiki et al., 1997; Yamaguchi et al., 2001). Interestingly, the presence of the disulfide bridge 
is required for formation of long and straight fibrils and reduction of the disulfide bond leads 
to an assembly of fibrils morphologically similar to those formed at pH 3.6 (Katou et al., 
2002). Interestingly, in low pH molecular dynamics simulations disappearance of the β-bulge 
is observed (Park and Saven, 2006), which suggests that its removal, whether by acid 
denaturation or as an effect of Pro32 isomerization, promotes amyloid fibril formation of 
hβ2m. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 4-2. Schematic representation of amyloid fibril formation by hβ2m 
(adapted from(Kelly, 2000). 
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Structural characterization of the partially unfolded intermediate ensembles and 
determination of the relation between these species and the morphology of the fully maturated 
fibrils are the key challenges in understanding the mechanism of amyloid fibril formation by 
hβ2m. 
 
4.1.3. Variants of hβ2m 
Numerous mutagenesis studies have been performed to gain insight into stabilization / 
destabilization of β-2-microglobulin. It has been generally observed that single residue 
mutations to proline within any of the seven native β-strands hinder aggregation (Chiba et al., 
2003), while side-chain truncations of buried hydrophobic residues led to significant 
destabilization of the protein, yet no spontaneous aggregation occurred at physiological pH 
(Smith et al., 2003). A naturally occurring asparagine deamidation at residue 17 (Odani et al., 
1990) was also shown to significantly destabilize the protein although, as in other destabilized 
mutants, acidification was still necessary for the N17D-hβ2m to aggregate in vitro (Kad et al., 
2001). 
 Another variant found in vivo is a result of removal of the N-terminal hexapeptide, 
which accounts for 30 % of hβ2m amyloid deposits in hemodialyzed patients (Linke et al., 
1987). From the structural point of view, only part of the β-sheet pairing is retained in the 
ΔN6 mutant by the stabilizing effect of the disulfide bond (Esposito et al., 2000). 
Perturbations of the tertiary structure resulting from the N-terminal truncation have such a 
pronounced effect on the stability of the protein that in contrast to other variants and the wild 
type protein, the ΔN6 mutant is able to form amyloid fibrils at pH 7.0. Addition of ΔN6-hβ2m 
was also shown to greatly accelerate the aggregation of full length hβ2m at physiological pH 
(Piazza et al., 2006). The high self-association tendency of ΔN6-hβ2m explains in vivo 
observations that this mutant was neither found in plasma nor in the insoluble non-fibrillar 
deposits in the heart and spleen (Stoppini et al., 2005). 
  Proteolysis of hβ2m by the lysine-specific Achromobacter protease I results in release 
of nine peptides, one of which (Ser20-Lys48, termed K3) spontaneously fibrillizes at low pH 
(Kozhukh et al., 2002). Recently, the structure of protofilament-like K3 fibrils was solved by 
solid-state NMR (Iwata et al., 2006). The fibrils were found to consist of in parallel, head-to-
head stacked K3 monomers in a β-strand-loop-β-strand conformation (Figure 4-3).  
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Figure 4-3. 3D structure of K3 fibrils.  
(a) Ribbon model of a K3 tetramer in parallel head-to-head arrangement with a +1 
register shift. (b) Conformation of a K3 monomer in fibrillar state (adapted from 
Iwata et al., 2006). 
 
Although the K3 peptide is not the only hβ2m fragment able to form fibrils (Ivanova et 
al., 2003; Jones et al., 2003), the authors provide invaluable information on the K3 fibrils and 
conclude that fibril formation of full length hβ2m might require tight packing of side chains 
on the intermolecular surface. Still, the structure of the wild type hβ2m fibrils remains 
unknown. 
 
4.2. Results 
4.2.1. Acid denaturation of hβ2m 
 Aggregation of human β-2-microglobulin in dialysis related amyloidosis requires 
partial unfolding of the protein, which can be achieved in vitro by acid denaturation. 
Structural rearrangements occurring upon unfolding are clearly reflected in the NMR spectra 
of hβ2m recorded under different conditions (Figure 4-4).  
4. Human beta-2-microglobulin 
71  
 
Figure 4-4. Unfolding of human β-2-microglobulin followed by NMR.  
1H,15N-HSQC spectra were acquired for hβ2m in 50 mM phosphate buffer at pH 
7.0 (blue), and in pure water at pH 3.6 (black) and pH 2.5 (red). 
 
At pH 7.0 the protein adopts the native immunoglobulin fold, which gives rise to a well-
dispersed spectrum characteristic for a protein rich in β-strands. At a pH value of 3.6 the 
partially unfolded state is populated to a high degree and conformational heterogeneity of the 
unstructured states leads to disappearance of many signals. A decrease of pH to 2.5 further 
denatures the protein and the signals not observable at pH 3.6 reappear in the spectrum. Due 
to the loss of β-sheet structure, the signals cover a very narrow ppm range and significant 
spectral overlap is observed. 
Unfolding of a protein changes its compaction and size, therefore the process of acid 
denaturation of hβ2m can be followed by a measurement of the protein’s diffusion properties. 
A diffusion ordered spectroscopy (DOSY) NMR experiment allows reflecting the 
hydrodynamic properties of a molecule as a decay of signal under pulsed field gradients. 
Figure 4-5 shows the signal decay curves of hβ2m at pH 7.0, 5.6, 3.6, and 2.5. 
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Figure 4-5. Changes in hydrodynamic radius of hβ2m upon acid denaturation. 
The changes in size were followed by a measurement of diffusion coefficients at 
pH 7.0 (black), 5.6 (green), 3.6 (blue), and 2.5 (red). Upon acid denaturation the 
diffusion coefficient of hβ2m decreases reflecting unfolding of the protein. 
 
Under physiological pH, the signal decay is faster as compared to the other conditions, 
which reports a smaller size. The well-defined fold increases the compactness of the 
polypeptide chain and therefore the molecule diffuses faster and a higher decrease of the 
signal is observed. In partially denatured states (pH 5.6 and 3.6), the signal decays slower 
evidencing an increase in the protein’s size. At pH 2.5, an even slower decay is observed due 
to further unfolding of the protein. Fitting of the decays to an exponential function and 
calculation of hydrodynamic radii using 1,4-dioxane as internal reference led to rH values of: 
1.8 nm at pH 7.0, 2.0 nm at pH 5.6 and pH 3.6, and 2.3 nm at pH 2.5. 
 
4.2.2. Structural analysis of the unfolded states 
4.2.2.1. pH 3.6 
 The highest population of partially unfolded states by β-2-microglobulin occurs at pH 
3.6 (McParland et al., 2000). However, as shown above in Figure 4-4, under these conditions 
only about 30 signals are observable. Due to severe line broadening caused by chemical 
exchange it is not possible to obtain assignment of these signals using standard NMR 
experiments. Recently, direct 13C detection emerged as a very useful technique to overcome 
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fast relaxation of 1H nuclei (Bertini et al., 2004; Bermel et al., 2005). The so-called protonless 
NMR experiments have not only proven useful in studies of proteins binding paramagnetic 
ions (Banci et al., 2006; Caillet-Saguy et al., 2006; Bertini et al., 2008) but also in case of 
intrinsically unstructured proteins (Bermel et al., 2006; Csizmok et al., 2008). We have 
applied the direct carbon detected CON and CACO experiments in order to detect the 
exchange-broadened resonances of the unfolding intermediate of human β-2-microglobulin 
(Figure 4-6).  
 
Figure 4-6. Direct carbon detection allows for observation of highly dynamic 
regions of hβ2m at pH 3.6. The 13C-CON spectrum allows for observation of 
resonances, which cannot be detected with standard 1H-detected experiments due 
to severe line broadening. The spectrum was recorded at 298 K on a 800 MHz 
Bruker Avance spectrometer equipped with a TCI cryo probehead using the pulse 
sequence depicted in Figure 2-5. 
 
Indeed, about 90 peaks were observable in the 13C-CON spectrum, however the 
spectrum was clearly showing two subpopulations of peaks with different intensity. The 
intense peaks corresponded to those residues, which were observable in standard proton-based 
NMR experiments, while the exchange-broadened peaks undetectable in 1H-detected 
experiments yielded signals with low intensity in the 13C-detected spectra. As a result, the 
three dimensional COCON experiment used for assignment of protonless NMR spectra failed 
to provide the sequential connectivity information necessary to attain the assignment. Instead, 
an approach combining 1H- and 13C-detected experiments was used. The backbone 
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assignment of hβ2m obtained with traditional experiments at pH 2.5 was first transferred to 
the 13C-CON spectrum. This resulted in assignment of 76 residues under these conditions. 
Then, a titration experiment was performed in which the pH was changed stepwise from 2.5 
to 3.6. Following this approach, a large number of resonances of the unfolding intermediate of 
hβ2m at pH 3.6 could be assigned (Figure 4-7a).  
Out of 94 possible assignments, 23 were missing at pH 3.6, out of which 18 residues 
were unassigned already at pH 2.5. For Leu23, Ile35, Glu36, and Val39 the changes in 
chemical shifts could be followed only in the first few steps of the pH titration experiment. 
Interestingly, the signals originating from these four residues disappeared around pH 3.1 and a 
general decrease in signal intensity was seen under these conditions, suggesting that the 
structural transition takes place at pH ~ 3.1 (Figure 4-7e). In addition, peak doubling was 
observed for a number of residues at pH 3.6 (G29, F30, H31, S52, S57, S61, L87 – see 
Figure 4-6) indicative of conformational heterogeneity of the partially unfolded intermediate 
ensembles of hβ2m. 
The analysis of signal intensities in the 13C-detected CON experiment (Figure 4-7b) 
reveals that residues in the central part of the protein (22-82) give rise to low intensity signals 
indicative of increased chemical exchange in this region. Furthermore, a comparison between 
13C’ chemical shift at pH 2.5 and 3.6 (Figure 4-7c) identifies residues 35-41, 46-49, 54-64, 
and 80-88 to have increased α-helical propensities at pH 3.6 with respect to pH 2.5, while in 
the C-terminal region the opposite effect is observed for residues 91-97, which display higher 
propensity for extended structure at pH 3.6. The largest downfield shifts (more α-helical or 
turn propensity) are seen for residues 64 and 80 lying at the edges of the exchange-broadened 
region 65-78.  
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Figure 4-7. Structural properties of hβ2m at pH 3.6.  
(a) Schematic representation of completeness of assignment; unassigned residues 
and prolines are highlighted in red and grey, respectively; blue color indicates 
residues for which signals could be observed only in the first few steps of the 
titration. (b) Signal intensities in the 13C-CON experiment at pH 2.5 (red) and pH 
3.6 (grey); noise level in the spectra is marked in cyan; missing assignments are 
indicated by asterisks for both conditions; structural elements found under native 
conditions and the position of the disulfide bridge are indicated above the plot. (c) 
Changes in 13C’ chemical shift upon pH change from 2.5 to 3.6; blue bars indicate 
residues for which the assignment at pH 3.6 was missing, and the value from pH 
3.1 was used for the calculation. (d) Secondary chemical shifts of hβ2m at pH 3.6 
calculated using the 13C’ chemical shift. (e) Excerpts from the 13C-CON spectra 
showing residues with the largest changes; pH values are: 2.5 (red), 2.7 (orange), 
2.9 (light grey), 3.1 (green), 3.3 (blue), and 3.6 (magenta). 
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In the CON experiment, the nitrogen chemical shift of residue i is correlated with the C’ 
chemical shift of residue i-1. Therefore, the values reported for residues 35, 54, 97, and 99 
might be influenced by sidechain protonation of the preceding aspartates, which occurs 
around pH 3.6. 
By applying carbon detected experiments, assignment of more than 80 % residues of the 
unfolded intermediate of hβ2m at pH 3.6 could be obtained. The assigned C’ chemical shifts 
were then used to calculate the secondary chemical shifts shown in Figure 4-7d. Stretches of 
negative secondary chemical shifts are found at pH 3.6 for residues 1-33, 45-55, and 83-99, 
indicating a propensity for extended structure in these regions. Due to chemical exchange, no 
clear indication of secondary structure preferences is observed in the central part of the 
protein (residues 65-82). 
 
4.2.2.2. pH 2.5 
 Although the partially unfolded intermediate of hβ2m is highly populated at pH 3.6, 
the most optimal aggregation conditions were found to be at an even lower pH. Amyloid 
fibrils formed by hβ2m at pH 2.5 are long and straight and closely resemble those extracted 
from patients, in contrast to short, worm-like aggregates obtained at pH 3.6. Therefore, it 
seems more disease relevant to investigate the structure of hβ2m intermediate and the amyloid 
fibrils formed at pH 2.5. To prevent spontaneous aggregation of the protein under the 
aggregation promoting conditions it is required that the ionic strength of the solution is kept at 
minimum. Therefore, the sample for investigation of secondary structure of monomeric β-2-
microglobulin at pH 2.5 was prepared by dissolving the protein in pure water without 
presence of any salt or buffer. Residue specific assignment was obtained using standard 3D 
(HA)CANNH and HNCO, and secondary chemical shifts (Figure 4-8) were calculated as 
described in 2.4.2. 
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Figure 4-8. Secondary chemical shifts of hβ2m at pH 2.5.  
Secondary structure elements present at pH 7.0 are indicated by black bars. 
 
Interestingly, even though the protein is largely unstructured under the studied 
conditions, a propensity for α-helical structure is found in regions corresponding to strands C 
and E, and the DE and EF loops. This is surprising as the native fold is formed only by β-
strands, which implies that major structural rearrangements occur upon acid denaturation of 
hβ2m. 
 
4.2.3. Observation of flexible regions in hβ2m fibrils 
 Aggregation of hβ2m was performed at 37 oC with agitation at 500 rpm, in a mixed 
buffer consisting of 25 mM sodium acetate and 25 mM sodium phosphate at pH 2.5. Even 
though fibril formation occurred already a few hours after the initiation of aggregation, it was 
necessary to continue the reaction for 7 days to fully convert all the monomer into fibrils 
(Figure 4-9). 
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Figure 4-9. Amyloid fibril formation by hβ2m.  
Negatively stained EM images were taken after (a) 1, (b) 3, and (c) 7 days of 
incubation at 37 oC. The white bar indicates a size of 200 nm. 
  
Mature fibrils were washed to remove residual monomer and filled into a 5 mm HR-
MAS rotor. Under magic angle spinning at 7.2 kHz, nitrogen and carbon HSQCs (Figure 4-
10), as well as 1H,1H- and HCCH-TOCSY spectra were acquired. Based on these experiments 
residue-type assignment was performed revealing the absence of signals from aspartates, 
cysteines, and phenylalanines. Furthermore, histidines (4 occurrences in the sequence), 
leucines (7 occurrences) and tyrosines (6 occurrences) yielded low intensity signals, 
suggesting that not all residues of each type are observable in the spectrum. 
 
 
 
 
 
 
Figure 4-10. NMR spectra of hβ2m fibrils under high-resolution magic angle 
spinning. (a) 1H,15N-HSQC, (b) 1H,13C-HSQC. Both spectra were recorded at 310 
K with MAS at 7.2 kHz. 
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 A sequence specific assignment could be obtained for majority of the observable 
peaks, based only on two-dimensional projections of HNCA and HNCO experiments (Figure 
4-11a). 
 
Figure 4-11. Identification of flexible regions in amyloid fibrils of hβ2m.  
(a) 2D projection of an HNCA spectrum used for assignment of signals from the 
flexible region. (b) Mapping of assigned HR-MAS peaks (red) onto the native 
fold. (c) Analysis of signal intensities in the flexible region reveals rapidly 
increasing rigidity when moving away from the N-terminus. 
 
Seventeen of a total of 22 signals in the 1H,15N-HSQC were sequentially assigned to the 
N-terminal residues reporting that the region corresponding to β-strand A in the native fold is 
flexible in the fibrillar form of β-2-microglobulin (Figure 4-11b). Furthermore, the analysis 
of signal intensity for residues 1-20 (Figure 4-11c) shows an exponential decay indicating a 
rapidly increasing rigidity while moving away from the N-terminus along the polypeptide 
chain. 
 
4.2.4. Mapping the core of hβ2m fibrils by H/D exchange 
 As described in section 1.2.1, NMR-detected proton / deuterium exchange experiment 
provides valuable information about the structure of amyloid fibrils. Using the 50 % H2O / 50 
% D2O buffer system for dissolution of the fibrils, the H/D exchange profile was studied for 
hβ2m fibrils. As a results of the experimental conditions used (see 3.2.3.2. for details), in the 
protection map depicted in Figure 4-12, residues that are solvent accessible in more than 50 
% in the fibrils will give rise to I/I0 values greater than 1 at the end of the back-exchange 
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process. Residues that are buried in the core will not be subject to significant H/D exchange, 
and for those residues the normalized intensity at the end of the back-exchange process will 
lay between 0.5 and 1.0, where 0.5 indicates full protection and 1.0 corresponds to 50 % 
protection in the fibril. 
 
Figure 4-12. H/D exchange map for fibrils of human β-2-microglobulin.  
The protection map was recorded after 7 days of exchange with D2O. Structural 
elements found in the native fold at physiological pH are indicated by black bars. 
Open circles indicate residues observable in HR-MAS spectra. 
 
As evidenced by the H/D exchange experiment, the N- and C-terminal regions of the 
protein show increased solvent exposure, while residues 20-90 are generally buried in the 
fibril core. The highest protection levels are seen in regions 21-29, 35-38 and 61-78, 
corresponding to strands B, C and E, and the EF loop. Since NMR-detection of exchange 
rates provides single residue resolution, further important observations can be made revealing 
details of the hβ2m fibril architecture. In regions corresponding to β-strands B and E, a slope 
in the I/I0 values is detected. In both these regions (23-30 and 61-70), the solvent protection 
decreases along the sequence. Since in the native fold strands B and E are arranged 
antiparallely, this finding suggests that a rearrangement of the strands occurs upon 
aggregation of the protein. 
Interestingly, even though solvent exchange and observability of signal in HR-MAS fall 
into different time regimes, a correlation between those two properties is seen for fibrils of 
human β-2-microglobulin. The solvent accessible residues from N- and C-termini are also 
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giving rise to peaks in HR-MAS spectra (indicated by open circles in Figure 4-12), therefore 
hinting that local flexibility of those regions occurs on a range of timescales. 
Taken together, our data provides strong evidence that the N- and C-termini are 
flexible in the amyloid fibrils of human β-2-microglobulin as evidenced by both high-
resolution magic angle spinning experiments and NMR-detected proton / deuterium exchange. 
 
4.3. Discussion 
Dialysis-related amyloidosis is caused by increased serum levels and spontaneous 
aggregation of human β-2-microglobulin in patients undergoing long-term hemodialysis. To 
cure and/or prevent the disease, the mechanism of amyloid fibril formation by hβ2m needs to 
be revealed and understood. Here, we have concentrated on two aspects of the fibrillization 
pathway.  
Firstly, using NMR secondary chemical shifts we have studied the structural properties 
of unfolding intermediates of hβ2m under aggregation prone conditions. At a pH value of 2.5, 
the protein forms amyloid fibrils in vitro which share a common architecture with the in vivo 
ones, as evidenced by a Fourier transform infrared spectroscopy (FTIR) study by Jahn and 
coworkers (Jahn et al., 2008). The secondary chemical shifts (Figure 4-13a) reveal that the 
protein displays a propensity to adopt α-helical conformation in regions 34-44, 58-68 and 73-
76. Our data are in general agreement with previously published observation of Katou and 
coworkers (Figure 4-13b), who reported α-helical propensities in regions corresponding to β-
strands C, D and E in the native fold (Katou et al., 2002). It should be noted however that an 
offset of ~0.5 ppm is present between the two datasets, which might be due to different 
random coil chemical shifts used in the calculation. 
 
Figure 4-13. Secondary chemical shifts report α-helical propensities in hβ2m at 
pH 2.5. A comparison between SCS (a) obtained in this study and (b) previously 
reported by Katou and coworkers (adapted from Katou et al., 2002). 
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Based on this information we have investigated the differences between the 
intermediate states at pH 2.5 and 3.6. In the latter case, the highest population of unfolded 
states has been reported (McParland et al., 2000). Previous attempts to obtain information 
about the structure of the unfolding intermediate at pH 3.6 were unsuccessful as increased 
conformational heterogeneity led to disappearance of many signals in the NMR spectrum 
(McParland et al., 2002). By applying direct 13C-detected experiments we were able to obtain 
more than 80 % assignment of hβ2m at pH 3.6 which allowed to identify regions undergoing 
severe conformational exchange, that are located around residues 35-41, 46-49, 54-64, and 
80-88 as evidenced by loss of signal in these regions and significant changes in secondary 
structure propensities (towards α-helical conformation) upon pH change from 2.5 to 3.6 
(Figure 4-7b,c). Furthermore, an increase in the propensity for extended structure was found 
in the C-terminal residues 82-99 (Figure 4-7d). Taken together our data suggest that the 
structural variations between the two partially unfolded states at pH 2.5 and 3.6, presented by 
different aggregation kinetics and fibril morphology, are located between residue ~22 and the 
C-terminus.  
Our findings also demonstrate that a significant amount of local structure is present in 
the acid-denatured intermediate ensembles of hβ2m, which is in agreement with a recent 
NMR study on dynamics of the unfolded intermediate of hβ2m at pH 2.5 (Platt et al., 2005). 
The authors report that although the N- and C-termini are predominantly unfolded in the acid-
denatured state, the experimental 15N transverse relaxation rates for residues 26-84 are much 
higher than the values predicted using a random polymer model containing a single disulfide 
bond between residues 25 and 80 (Figure 4-14). This correlates well with the lower signal 
intensities observed for those residues in the 13C-CON spectra (see Figure 4-7b). 
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Figure 4-14. Residue-specific R2 relaxation rates for hβ2m at pH 2.5.  
R2 rates were measured in (a) water and (b) 1.3 M urea. Position of β-strands in 
the native state is indicated by black bars, aromatic residues are marked by green 
diamonds. The predicted random coil R2 rates are shown in cyan. Red line 
represents fitting of the experimental data to a random coil model that contains 
two regions of non-random structure located around the hydrophobic clusters 29-
51 and 59-78 (adapted from Platt et al., 2005). 
 
Importantly, the residues with highest 15N R2 relaxation rates became observable only 
in presence of 1.3 M urea (Figure 4-14b), and similarly to our data assignment of this region 
could not be obtained in a non-denaturing environment (Figure 4-14a). The significance of 
the predominantly hydrophobic residues 62-70 for the aggregation of hβ2m is further 
supported by subsequent mutagenesis experiments from the same research group. The study 
shows that mutations of residues in this region (in particular F62, Y63, L65, Y67 and F70) 
designed to decrease hydrophobicity, change the kinetics of aggregation and lead to an 
increase in the lag phase. The authors conclude that non-native hydrophobic clustering might 
be the mechanism of initiation of hβ2m aggregation (Platt et al., 2008; Routledge et al., 
2009). 
 
 The second part of our study focused on the structure of mature hβ2m fibrils obtained 
in vitro at pH 2.5. Using high-resolution magic angle spinning, we reported observation of 
flexible regions in the fibrillar form of hβ2m located at the N- and C-termini of the 
polypeptide chain (see Figure 4-12). This finding is in line with a previous urea-denaturation 
study (McParland et al., 2002), which concluded that unfolding of strands A and G might be 
sufficient to initiate the aggregation of human β-2-microglobulin, however these data were 
obtained at pH 3.6, where the fibrils are known to have a different morphology. 
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 The results of the HR-MAS experiments were further confirmed by amide proton 
exchange rates investigated by NMR-detected H/D exchange. The experimental data (Figures 
4-12 and 4-15a) report on increased deuterium incorporation in the N- and C-terminal regions 
of the protein while the amide protons of residues 20-85 are protected from exchange with the 
solvent. The lower protection of the N-terminus with respect to the C-terminus could explain 
the results of a limited pepsin proteolysis study of hβ2m fibrils formed at pH 2.5, where a 
single cleavage site at Val9 was found (Myers et al., 2006). 
 
Figure 4-15. Deuterium incorporation into amyloid fibrils of hβ2m.  
(a) The levels of deuterium incorporation were calculated by normalizing the 
inversed I24h/I0 values depicted in Figure 4-12. (b) H/D exchange of hβ2m fibrils 
as reported by Hoshino and coworkers (Hoshino et al., 2002). 
 
While our data are in overall agreement with published H/D exchange data (Figure 4-
15b) (Hoshino et al., 2002), we provide new information on amide proton exchange rates in 
regions corresponding to the disulfide-bridged β-strands B and F, which were previously not 
detected due to the use of a different buffer system for dissolution of amyloid fibrils. Here we 
showed that the above-mentioned regions stay protected from solvent exchange. This finding 
is of high importance considering that reduction of the disulfide bridge between cysteins 25 
and 80 leads to amyloid fibrils of different morphology (Katou et al., 2002).  
The H/D exchange experiment also shows that the highest protection from exchange 
occurs in regions corresponding to strands B, C and E, and the EF loop. This matches the 
positions of the aromatic residues and regions with the highest R2 relaxation rates shown in 
Figure 4-14b (Platt et al., 2005). Strikingly, a very good agreement is found between the 
signal intensities in the spectra of the partially unfolded intermediates of hβ2m and the 
solvent protection pattern in the fibril (Figure 4-16). Regions with the lowest deuterium 
incorporation in the fibrils located around residues 22-25 and 61-78 correspond to the residues 
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giving lowest signal in the 13C-CON experiment. Moreover, a slight increase of solvent 
exposure of residues 29-60 correlates well with the increase of signal intensities in the spectra 
of the partially unfolded state, thereby proving a close relationship between the dynamics of 
the precursor ensembles with morphology of the mature fibrils. This region includes the β-
strand D, which was shown to adopt different conformations under native conditions when 
studied with different techniques. In the crystal structure of hβ2m bound to the major 
histocompatibility complex-I (MHC-I) the strand is broken by a β-bulge (Khan et al., 2000), 
while in crystals of isolated hβ2m β-strand D is long and continuous (Trinh et al., 2002). In 
the NMR structure in solution strand D exists as two short strands D1 (50-52) and D2 (55-57) 
(Okon et al., 1992) and displays conformational dynamics (Verdone et al., 2002). 
 
 
Figure 4-16. Relationship between the dynamics of the hβ2m intermediate and 
structural architecture of the fibrils. Grey bars represent signal intensities in the 
13C-CON experiment at pH 2.5, relative deuterium incorporation into amyloid 
fibrils is shown in blue. Structural elements of native hβ2m are indicated above 
the plot, with the conformationally heterogeneous strand D indicated with a 
hashed bar; green circles mark positions of aromatic residues in the sequence; 
residues encompassed by the K3 peptide and structure of K3 fibrils are shown in 
red (based on Kozhukh et al., 2001). 
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Furthermore, two peptides related to the highly protected regions around strands B and 
E were reported to self-associate in vitro forming amyloid fibrils. The first region is 
encompassed by the K3 peptide (residues 20-41) released from hβ2m as a product of 
proteolytic cleavage of hβ2m with Achromobacter protease I (Kozhukh et al., 2002). 
Interestingly, the positions of β-strands in the amyloid fibrils of the K3 peptide match the dips 
around residues 23 and 36 in H/D exchange pattern of the full-length hβ2m fibrils (Figure 4-
16). The second aggregation-prone peptide (residues 59-71) includes the hydrophobic region 
of strand E (Jones et al., 2003). 
The H/D exchange data is additionally summarized in Figure 4-17 by mapping the 
levels of deuterium incorporation into the amyloid fibrils onto the native fold of hβ2m. 
 
 
 
Figure 4-17. Mapping of hβ2m amyloid fibril solvent protection levels onto the 
native fold. The I24h/I0 values were color-coded using the thresholds: 0.5-0.65 
(red), 0.65-0.8 (orange), 0.8-1.0 (yellow), >1.0 (white). 
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In summary, we report that: 
(i) signals of the partially unfolded intermediate ensembles broadened due to 
conformational exchange can be observed and assigned using direct carbon detected 
NMR experiments, 
(ii) signal intensities in the 13C-detected spectra correlate with previously published 15N 
transverse relaxation rates, 
(iii) structural differences between the partially unfolded states at pH 2.5 and 3.6 resulting 
in different fibril morphology are located in the region between residue 22 and the C-
terminus; with respect to pH 2.5, the unfolding intermediate at pH 3.6 has increased α-
helical propensities in regions 35-41, 46-49, 54-64 and 80-88, while an increase in 
propensity for extended structure is found in the C-terminal residues 91-97, 
(iv) flexible regions in amyloid fibrils of hβ2m are present at the N- and C-termini and can 
be observed and sequentially assigned using high-resolution magic angle spinning 
technique, 
(v) the HR-MAS data correlate well with increased solvent exposure of the N- and C-
terminal regions in the H/D exchange experiment, 
(vi) highest protection rates in fibrils of hβ2m are found for residues 21-29, 35-38 and 61-
78, which reflects the position of aromatic residues in the sequence and provides 
evidence that hydrophobic clustering might be the mechanism of initiation of hβ2m 
aggregation, 
(vii) a close relationship is seen between the dynamic properties of the partially unfolded 
intermediate species and the morphology of mature amyloid fibrils of hβ2m. 
A subsequent solid-state NMR investigation would be helpful to determine the exact number 
and positions of β-strands within the core of hβ2m fibrils and suggest a structural model for 
these aggregates. 
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Appendix A. Charge-induced molecular alignment of 
intrinsically disordered proteins 
 
 
In form of a reprint, a study concerning the effects of electrostatic interactions on 
molecular alignment of intrinsically disordered proteins, is presented here.  
Intrinsically disordered or unstructured proteins (IUPs) play key roles in normal and 
pathological biochemical processes. Despite their importance for function, this category of 
proteins remains beyond the reach of classical structural biology because of their inherent 
conformational heterogeneity. Recently, it was shown that the local conformational behavior 
of IUPs can be described using a simple model based on residue-specific Phi/Psi propensities 
and that residual dipolar couplings (RDCs) observed in IUPs can be predicted from this model 
assuming a steric interaction between the protein and the alignment medium (1, 2). In 
addition, we recently showed that RDCs are also sensitive detectors of transient long-range 
interactions in IUPs (3). 
It is demonstrated here, that the assumption of a steric-like interaction (4) between 
intrinsically disordered proteins and the alignment medium is only valid in case of uncharged 
alignment media. Alignment of intrinsically disordered proteins in charged media depends 
critically on electrostatic interactions, especially in charged regions of the protein, scales with 
ionic strength of the solution and can be predicted using a simplified electrostatic model (5). 
This has important consequences for the RDC-based interpretation of the structure and 
dynamics of the unstructured state. 
 
1. Bernado P, Blanchard L, Timmins P, Marion D, Ruigrok RW, Blackledge M. Proc. 
Natl. Acad. Sci. USA. 2005, 102, 17002-17007 
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Appendix B. Chemical shift lists 
 
Chemical shift list of 13C-CON of hβ2m 
 
 pH 2.5 pH 3.6 
 N C' N C' 
Ile 1 124,23 175,47 124,21 175,47 
Gln 2 125,63 175,52 125,63 175,53 
Arg 3 123,74 176,03 123,74 176,02 
Thr 4 117,96  117,95  
Pro 5  176,54  176,52 
Lys 6 121,88 176,38 121,90 176,37 
Ile 7 122,54 175,84 122,57 175,83 
Gln 8 125,30 175,27 125,30 175,25 
Val 9 122,00 175,65 122,03 175,63 
Tyr 10 124,34 175,59 124,39 175,57 
Ser 11 117,86 173,95 117,90 173,94 
Arg 12 122,81 175,67 122,71 175,67 
His 13 120,02  120,16  
Pro 14  176,50  176,49 
Ala 15 124,59 177,72 124,50 177,72 
Glu 16 119,67 175,67 119,89 175,67 
Asn 17 120,09 175,63 120,16 175,67 
Gly 18 109,30 174,13 109,28 174,15 
Lys 19 120,60 176,69 120,57 176,69 
Ser 20 116,40 174,13 116,39 174,15 
Asn 21 120,60 174,83 120,57 174,86 
Phe 22 120,14 175,36 120,16 175,38* 
Leu 23 122,50 176,51 122,40* 176,64 
Asn 24 118,32 174,98 118,72 175,00 
Cys 25 118,43  118,36  
Val 27  175,75   
Ser 28 118,67 174,96  174,93 
Gly 29 110,56 173,38 110,50 173,36 
Phe 30 120,29 174,89 120,18 174,83 
His 31 122,35  122,34  
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 pH 2.5 pH 3.6 
 N C’ N C’ 
Pro 32  176,75  176,75 
Ser 33 115,69 174,41 115,51 174,38 
Asp 34 120,66 175,04 121,12 175,18* 
Ile 35 119,98 175,90 119,94* 175,92* 
Glu 36 123,36 176,12 123,35* 176,23 
Val 37 120,39 176,00 119,96 176,08 
Asp 38 121,39 175,24 121,85  
Leu 39 122,61 177,47  177,55 
Leu 40 121,53 177,87 121,43 178,06 
Lys 41 120,87 176,82 120,66 176,83 
Asn 42 118,87 175,88 118,84 175,88 
Gly 43 108,47 174,19 108,42 174,19 
Glu 44 119,54 175,69 119,65 175,69 
Arg 45 121,53 176,12 121,47 176,17 
Ile 46 121,85 176,01 121,87 176,04 
Glu 47 123,73 175,78 123,61 175,86 
Lys 48 121,82 176,25 121,64 176,28* 
Val 49 121,43 176,08 121,28* 176,05 
Glu 50 123,47 175,81 123,52 175,81 
His 51 118,78 174,23 118,70 174,24 
Ser 52 115,89 174,15 116,20 174,07 
Asp 53 121,04 175,13 121,43 175,25 
Leu 54 122,33 177,28 122,03 177,41 
Ser 55 115,59 174,28 115,58 174,36 
Phe 56 121,58 175,82 121,42 175,81 
Ser 57 116,04 175,02 115,74 175,06 
Lys 58 122,07 176,69 122,20 176,81 
Asp 59 118,54  118,30  
Trp 60  176,62  176,74 
Ser 61 115,39  115,25  
Phe 62  175,96   
Tyr 63 119,12 176,04  176,34 
Leu 64 119,65  119,60  
Thr 68  174,58   
Glu 69 120,52 174,62   
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 pH 2.5 pH 3.6 
 N C’ N C’ 
Phe 70 120,72    
Thr 73  175,18  175,16 
Glu 74 121,37  121,40  
Glu 77  176,01  176,00 
Tyr 78 119,47  119,23  
Ala 79  177,53  177,73 
Cys 80 117,35  116,90  
Val 82  175,52  175,59 
Asn 83 122,57 174,72 121,78 174,73 
His 84 119,31 173,90 118,97 173,94 
Val 85 121,92 175,90 121,52 175,88 
Thr 86 119,45 174,14 119,07 174,19 
Leu 87 125,74 176,98 125,52 177,01 
Ser 88 116,97 173,92 116,78 173,92 
Gln 89 122,99  122,94  
Pro 90  176,54  176,50 
Lys 91 121,53 176,27 121,29 176,20 
Ile 92 122,72 175,90 122,50 175,85 
Val 93 125,13 175,70 124,88 175,54 
Lys 94 125,00 175,82 124,92 175,74 
Trp 95 122,17 175,72 122,52 175,65 
Asp 96 120,93 174,60 121,28 174,91 
Arg 97 120,63 175,60 120,37 175,61 
Asp 98 119,03 174,64 119,63 174,56 
Met 99 121,32  123,25  
 
          * - resonance not observable at pH 3.6; chemical shift value corresponds to pH 2.9 
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Chemical shift list of hβ2m in 4M GdnSCN 
 
 N HN Cα Cβ 
Ile 1 124,17 8,65 61,85 39,47 
Gln 2 125,55 8,63 56,18 30,03 
Arg 3 124,05 8,58 56,67 31,63 
Thr 4 117,00 8,38 59,95 70,34 
Pro 5   63,76 32,72 
Lys 6 122,47 8,48 57,05 33,43 
Ile 7 122,03 8,20 61,71 39,26 
Gln 8 125,15 8,52 56,19 29,85 
Val 9 121,82 8,22 62,98 33,39 
Tyr 10 123,86 8,36 58,46 39,37 
Ser 11 117,55 8,31 58,53 64,79 
Arg 12 123,16 8,39 57,05 31,38 
His 13 119,18 8,51 53,74 29,10 
Pro 14   64,15 32,63 
Ala 15 124,84 8,62 53,29 19,59 
Glu 16 119,99 8,47 56,37 29,12 
Asn 17 119,72 8,58 53,69 39,43 
Gly 18 109,95 8,53 46,00  
Lys 19 121,32 8,36 56,95 33,60 
Ser 20 116,76 8,47 58,69 64,45 
Asn 21 121,35 8,56 53,72 39,31 
Phe 22 120,71 8,33 58,58 39,94 
Leu 23 122,65 8,38 55,61 42,80 
Cys 25 119,39 8,44 53,70 39,29 
Tyr 26 123,33 8,35 58,63 39,28 
Val 27 121,29 8,26 63,15 33,32 
Ser 28 119,38 8,43 58,82 64,66 
Gly 29 111,05 8,43 45,64  
Phe 30 121,11 8,32 58,47 40,25 
His 31 122,15 8,35 53,45 29,21 
Pro 32   63,58 32,59 
Ser 33 116,43 8,59 58,81 64,59 
Asp 34 121,53 8,63 53,68 38,75 
Ile 35 120,49 8,15 61,91 39,13 
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 N HN Cα Cβ 
Glu 36 124,25 8,44 56,54 29,08 
Val 37 120,65 8,19 63,17 33,23 
Asp 38 122,29 8,59 53,58 38,56 
Leu 39 123,10 8,32 55,83 42,74 
Leu 40 121,98 8,25 55,83 42,65 
Lys 41 121,81 8,36 56,95 33,58 
Asn 42 119,19 8,49 53,69 39,23 
Gly 43 109,59 8,49 46,10  
Glu 44 120,09 8,36 56,47 29,36 
Arg 45 122,42 8,46 56,49 31,19 
Ile 46 122,14 8,29 61,95 39,17 
Glu 47 124,14 8,44 56,54 29,05 
Lys 48 123,53 8,40 56,74 33,58 
Val 49 121,48 8,27 63,16 33,48 
Glu 50 123,58 8,50 56,53 29,15 
His 51 119,41 8,58 55,98 29,31 
Ser 52 116,90 8,53 58,83 64,63 
Asp 53 121,78 8,74 53,68 38,77 
Leu 54 122,49 8,33 55,78 42,59 
Ser 55 116,28 8,32 58,85 64,40 
Phe 56 122,45 8,31 58,57 40,01 
Ser 57 116,97 8,30 58,63 64,69 
Lys 58 123,25 8,35 57,05 33,16 
Asp 59 119,56 8,48 53,59  
Trp 60 122,14 8,19 58,42 30,04 
Ser 61 116,49 8,13 58,91 64,33 
Phe 62 122,80 8,16 59,61 39,81 
Tyr 63 120,22 8,08 59,19 39,28 
Leu 64 121,90 8,07 56,18 42,69 
Leu 65 121,68 8,07 56,18 42,69 
Tyr 66 119,60 8,08 58,98 39,33 
Tyr 67 120,29 8,17 58,95 39,18 
Thr 68 114,20 8,07 62,05 70,66 
Glu 69 122,22 8,31 56,69 29,15 
Phe 70 121,66 8,36 58,32 40,34 
Thr 71 118,71 8,15 59,80 70,55 
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 N HN Cα Cβ 
Pro 72   63,99 32,58 
Thr 73 113,76 8,31 62,27 70,62 
Glu 74 122,57 8,43 57,00 29,25 
Lys 75 121,99 8,43 57,20 33,43 
Glu 77 120,93 8,34 56,90 29,05 
Tyr 78 120,36 8,29 58,47 39,13 
Ala 79 124,30 8,27 53,54 19,89 
Cys 80 117,48 8,42 55,78 41,01 
Val 82 120,67 8,24 63,11 33,28 
Asn 83 122,31 8,51 53,69 39,49 
His 84 119,58 8,55 55,67 29,51 
Val 85 121,75 8,39 63,20 33,29 
Thr 86 118,93 8,44 62,09 70,59 
Leu 87 125,42 8,43 55,45 42,85 
Ser 88 116,96 8,42 58,59 64,58 
Gln 89 122,79 8,49 54,13 29,41 
Pro 90   63,87 32,92 
Lys 91 122,58 8,47 56,95 33,38 
Ile 92 122,80 8,23 61,63 39,13 
Val 93 124,69 8,22 62,55 33,23 
Lys 94 125,33 8,33 57,20 33,48 
Trp 95 121,62 8,11 57,55 30,01 
Asp 96 120,36 8,37 53,38 38,68 
Arg 97 121,41 8,24 57,10 30,99 
Asp 98 119,59 8,53 53,69 38,73 
Met 99 122,51 8,25 55,83 33,12 
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Chemical Shift list of humPrP23-173 in 2M GdnSCN 
 
 N HN Cα Cβ 
Lys 23 125,65 8,53 56,26 29,88 
Lys 24 126,06 8,47 56,20 33,43 
Arg 25 123,66 8,35 54,30 30,73 
Pro 26   63,52 32,76 
Lys 27 122,58 8,35 54,52 32,76 
Gly 30 109,20 8,36 45,58  
Trp 31 121,38 8,15 57,89 30,10 
Gly 35 109,20 8,36 45,58  
Ser 36 115,82 8,35 58,85 64,13 
Arg 37 123,03 8,37 56,74 31,27 
Gly 40 109,26 8,19 45,59  
Gln 41 120,03 8,31 56,32 29,74 
Gly 42 110,54 8,57 45,46  
Ser 43 116,87 8,31 56,48 63,63 
Pro 44   64,07 32,15 
Gly 45 109,31 8,49 45,58  
Gly 46 109,09 8,30 45,65  
Asn 47 119,19 8,44 53,31 38,21 
Gly 54 109,20 8,36 45,58  
Gly 55 109,20 8,36 45,58  
Gly 56 109,09 8,30 45,65  
Trp 57 121,38 8,15 57,89 30,10 
Gly 58 110,93 8,44 45,80  
Gln 59 120,56 8,15 54,10 29,30 
Pro 60   63,64 32,30 
His 61 118,39 8,58 55,60 29,22 
Gly 62 110,26 8,48 45,72  
Gly 63 109,20 8,36 45,58  
Gly 64 109,20 8,36 45,58  
Trp 65 121,38 8,15 57,89 30,10 
Gly 66 110,79 8,40 45,47  
Gln 67 120,56 8,15 54,10 29,30 
Pro 68   63,64 32,30 
His 69 118,39 8,58 55,60 29,22 
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 N HN Cα Cβ 
Gly 70 110,26 8,48 45,72  
Gly 71 109,20 8,36 45,58  
Gly 72 109,20 8,36 45,58  
Trp 73 121,38 8,15 57,89 30,10 
Gly 74 110,79 8,40 45,47  
Gln 75 120,56 8,15 54,10 29,30 
Pro 76   63,64 32,30 
His 77 118,39 8,58 55,60 29,22 
Gly 78 110,26 8,48 45,72  
Gly 79 109,20 8,36 45,58  
Gly 80 109,20 8,36 45,58  
Trp 81 121,38 8,15 57,89 30,10 
Gly 82 110,79 8,40 45,47  
Gln 83 120,56 8,15 54,10 29,30 
Pro 84   63,64 32,30 
His 85 118,39 8,58 55,60 29,22 
Gly 86 110,26 8,48 45,72  
Gly 87 109,20 8,36 45,58  
Gly 88 109,20 8,36 45,58  
Trp 89 121,38 8,15 57,89 30,10 
Gly 90 111,01 8,44 45,76  
Gln 91 119,88 8,29 56,66 28,68 
Gly 92 110,43 8,56 45,60  
Gly 93 109,20 8,36 45,58  
Gly 94 109,20 8,36 45,58  
Thr 95 113,32 8,23 62,13 70,12 
His 96 120,43 8,59 55,81 28,91 
Ser 97 116,82 8,39 58,96 63,98 
Gln 98 122,28 8,56 56,40 29,37 
Asn 100   52,67 39,33 
Lys 101 122,58 8,06 54,69 33,01 
Pro 102   63,44 32,36 
Ser 103 116,55 8,43 58,35 64,32 
Lys 104 124,02 8,34 54,63 33,05 
Pro 105   63,51 32,62 
Lys 106 122,09 8,48 56,93 33,31 
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 N HN Cα Cβ 
Thr 107 114,61 8,21 61,78 70,66 
Asn 108 121,40 8,48 52,70 39,34 
Lys 110 122,96 8,40 56,73 33,67 
His 111 118,84 8,45 55,88 28,87 
Ala 113 125,81 8,49 53,29 19,45 
Gly 114 108,88 8,44 45,65  
Ala 115 124,24 8,26 53,02 19,54 
Ala 116 123,03 8,36 52,93 19,38 
Ala 117 123,16 8,22 52,77 19,37 
Ala 118 123,15 8,28 53,09 19,42 
Gly 119 108,09 8,37 45,46  
Ala 120 124,03 8,17 52,71 19,67 
Val 121 119,61 8,19 62,63 32,97 
Val 122 124,19 8,28 62,97 33,01 
Gly 123 113,03 8,54 45,53  
Gly 124 109,20 8,36 45,58  
Leu 125 121,93 8,35 55,98 42,69 
Met 129 121,68 8,37 56,17 33,24 
Leu 130 123,05 8,17 56,03 42,58 
Gly 131 110,01 8,47 45,81  
Ser 132 115,86 8,31 58,70 64,23 
Ala 133 125,95 8,50 53,37 19,38 
Met 134 118,50 8,30 56,08 33,22 
Ser 135 116,79 8,26 58,38 64,20 
Arg 136 123,53 8,28 54,49 30,68 
Ile 139 124,80 8,08 61,36 39,00 
His 140 122,65 8,44 55,05 29,33 
Phe 141 122,47 8,40 58,45 39,96 
Gly 142 111,01 8,45 45,71  
Ser 143 115,82 8,35 58,85 64,13 
Asp 144 120,81 8,59 53,53 38,07 
Glu 146 120,77 8,28 56,39 28,82 
Asp 147 118,97 8,31 53,68 38,09 
Tyr 149 120,05 8,13 59,26 38,78 
Tyr 150 120,85 8,02 59,31 39,01 
Asn 153 118,75 8,34 39,13 53,97 
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 N HN Cα Cβ 
His 155 119,01 8,49 55,72 29,06 
Arg 156 121,76 8,20 56,42 31,52 
Pro 158 117,75 8,47 63,92 32,18 
Asn 159 117,84 8,47 53,76 39,03 
Val 161 121,03 8,11 62,99 33,07 
Tyr 162 123,45 8,17 58,02 39,49 
Tyr 163 122,58 8,11 58,01 39,47 
Arg 164 124,37 8,13 54,23 30,93 
Pro 165   63,59  
Met 166 119,97 8,43 56,32 32,65 
Asp 167 122,44 8,50 52,71 39,79 
Tyr 169 120,40 8,20 58,04 39,04 
Ser 170 116,61 8,21 58,42 64,06 
Asn 171 121,14 8,52 53,62 39,19 
Gln 172 120,37 8,42 56,22 29,89 
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Appendix C. H/D exchange data of humPrP23-159 
 
Changes in signal intensity during the back-exchange process  
of humPrP23-159 after 3 days of H/D exchange 
 
 I24h/I0  I24h/I0  I24h/I0 
Lys 24 1,67 Gly 74 1,82 Gly 114 1,08 
Arg 25 5,08 Gln 75 1,52 Ala 115 0,95 
Lys 27 3,29 His 77 1,43 Ala 116 1,15 
Gly 30 1,31 Gly 78 1,59 Ala 117 0,98 
Trp 31 2,15 Gly 79 1,38 Ala 118 1,01 
Gly 35 1,27 Gly 80 1,47 Gly 119 1,30 
Ser 36 1,75 Trp 81 2,10 Ala 120 1,45 
Arg 37 1,43 Gly 82 1,82 Val 121 0,77 
Gly 40 2,69 Gln 83 1,52 Val 122 0,68 
Gln 41 1,96 His 85 1,43 Gly 123 0,78 
Ser 43 1,42 Gly 86 1,59 Gly 124 0,83 
Gly 45 1,86 Gly 87 1,38 Leu 125 0,84 
Gly 46 1,26 Gly 88 1,47 Gly 126 0,92 
Asn 47 1,80 Trp 89 2,10 Gly 127 0,85 
Gly 54 1,45 Gly 90 1,83 Met 129 0,76 
Gly 55 1,31 Gln 91 1,91 Leu 130 0,65 
Gly 56 1,31 Gly 92 1,88 Ser 132 0,69 
Trp 57 2,20 Gly 93 1,33 Ala 133 0,68 
Gly 58 1,83 Gly 94 1,47 Met 134 0,76 
Gln 59 1,52 Thr 95 1,43 Ser 135 0,74 
His 61 1,43 His 96 1,32 Arg 136 0,66 
Gly 62 1,59 Ser 97 1,92 Ile 139 0,55 
Gly 63 1,38 Gln 98 1,83 His 140 1,16 
Gly 64 1,47 Lys 101 2,32 Phe 141 1,04 
Trp 65 2,10 Ser 103 1,51 Gly 142 1,08 
Gly 66 1,82 Lys 104 1,98 Ser 143 1,34 
Gln 67 1,52 Lys 106 1,75 Asp 144 1,46 
His 69 1,43 Thr 107 2,65 Glu 146 1,22 
Gly 70 1,59 Asn 108 1,27 Asp 147 1,49 
Gly 71 1,38 Lys 110 1,07 Tyr 149 4,68 
Gly 72 1,47 His 111 1,14 His 155 1,46 
Trp 73 2,10 Ala 113 1,10 Arg 156 2,82 
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Appendix D. CS-Rosetta output table 
 
Ten best 9-residue fragments selected by CS-Rosetta  
in hybrid mode for the Met112-Phe141 input sequence. 
 
Legend: 
Q1,QN – first and last residue of query sequence 
Q_SEQ – query sequence 
PDB – name of pdb file containing the found fragment 
R1, RN – first and last residue of found fragment in the pdb file 
ROS – raw Rosetta score 
SEC_ST – secondary structure of found fragment in pdb (L: loop, H: helix, E: extended) 
SEQ – sequence of found fragment 
CS – chemical shift based score 
 
Q1 QN Q_SEQ PDB  R1  RN ROS SEC_ST SEQ CS 
1 9 MAGAAAAGA 2YVV.pdb 255 263 1,69 LLLLLLLLL GAGTAAQGI 1,66
1 9 MAGAAAAGA 1KVE.pdb 16 24 1,88 LLLLLLLLL IAGCSGAAT 2,59
1 9 MAGAAAAGA 1KQF.pdb 978 986 2,28 LLLLLLLLL FEGVARKGY 2,70
1 9 MAGAAAAGA 1OQV.pdb 146 154 2,35 LLLEHHHLL SAAAAETGV 2,81
1 9 MAGAAAAGA 1U7G.pdb 86 94 2,30 LLLLLEELL IELTAVMGS 3,01
1 9 MAGAAAAGA 2AXC.pdb 25 33 2,28 LLLLELLLL VAAPMAFGF 3,07
1 9 MAGAAAAGA 1TMO.pdb 404 412 1,68 LLLLLLLLL SSGAAAPGA 3,19
1 9 MAGAAAAGA 1KVE.pdb 11 19 2,35 LLLLLLLLL TTIAAIAGC 3,20
1 9 MAGAAAAGA 1IO1.pdb 344 352 2,35 LLLLLLLLL LAEAAATTT 3,23
1 9 MAGAAAAGA 1TMO.pdb 146 154 2,17 LLLLLLLLL QTGWRATGQ 3,31
2 10 AGAAAAGAV 2YVV.pdb 256 264 1,92 LLLLLLLLL AGTAAQGIY 1,86
2 10 AGAAAAGAV 2QWU.pdb 64 72 2,24 LLLLLELEE ADSATAAAS 2,32
2 10 AGAAAAGAV 1TMO.pdb 405 413 1,87 LLLLLLLLL SGAAAPGAF 2,47
2 10 AGAAAAGAV 1ZJA.pdb 536 544 2,46 LLLLLLLEE APAAGAASL 2,48
2 10 AGAAAAGAV 2QO3.pdb 514 522 2,06 HLLLLLLLE AGAATADAV 2,53
2 10 AGAAAAGAV 2Q7D.pdb 336 344 2,47 LLLLLLLLL TAMAATGDV 2,60
2 10 AGAAAAGAV 1W79.pdb 202 210 2,50 LLLLLLLEE AGSANTLVI 2,63
2 10 AGAAAAGAV 1KQF.pdb 979 987 2,34 LLLLLLLLL EGVARKGYI 2,64
2 10 AGAAAAGAV 1YQ5.pdb 127 135 2,03 LLLLELLLE DGAALSNYI 2,72
2 10 AGAAAAGAV 1S7M.pdb 26 34 1,78 LLLLLLLLE AGANNANTI 3,07
3 11 GAAAAGAVV 1TYV.pdb 338 346 2,49 LLLLLLEEE DCAGSGAYL 1,63
3 11 GAAAAGAVV 1PMH.pdb 122 130 2,21 ELLLLLEEE ITANAGKKV 1,90
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3 11 GAAAAGAVV 2J5V.pdb 271 279 2,48 LLLLLLEEE GAPPAGEIT 2,08
3 11 GAAAAGAVV 2YVV.pdb 257 265 1,84 LLLLLLLLL GTAAQGIYI 2,09
3 11 GAAAAGAVV 2QWU.pdb 65 73 2,35 LLLLELEEE DSATAAASV 2,38
3 11 GAAAAGAVV 1TMO.pdb 406 414 2,52 LLLLLLLLL GAAAPGAFP 2,38
3 11 GAAAAGAVV 1XDN.pdb 100 108 2,39 LLLLLLEEE GLSRVGRLV 2,46
3 11 GAAAAGAVV 1YQ5.pdb 128 136 1,41 LLLELLLEE GAALSNYII 2,65
3 11 GAAAAGAVV 2B2A.pdb 119 127 2,16 LLEEELLEE GTTTIGFYV 2,65
3 11 GAAAAGAVV 1XC3.pdb 69 77 2,45 LLLLLLLEL TSQTYGTIT 3,02
4 12 AAAAGAVVG 1HX6.pdb 58 66 2,47 LLLLLEEEE PANVGIVKG 1,42
4 12 AAAAGAVVG 1TYV.pdb 339 347 2,66 LLLLLEEEE CAGSGAYLL 1,63
4 12 AAAAGAVVG 1PMH.pdb 123 131 1,95 LLLLLEEEE TANAGKKVK 1,83
4 12 AAAAGAVVG 2A5Z.pdb 221 229 2,50 LLLLLEEEE ADNATAHIG 2,45
4 12 AAAAGAVVG 1XC3.pdb 70 78 2,62 LLLLLLELL SQTYGTITA 2,70
4 12 AAAAGAVVG 1J30.pdb 71 79 2,65 LLLLLLELL DPATDKPIG 2,72
4 12 AAAAGAVVG 1YQ5.pdb 129 137 2,49 LLELLLEEE AALSNYIIN 2,74
4 12 AAAAGAVVG 2QWU.pdb 66 74 2,60 LLLELEEEE SATAAASVI 2,77
4 12 AAAAGAVVG 2AXT.pdb 450 458 2,33 HHLLLLLLL AAAAGFEKG 3,07
4 12 AAAAGAVVG 1YO6.pdb 141 149 2,59 LLLLLEEEE SVSRAAVIT 3,08
5 13 AAAGAVVGG 1HX6.pdb 59 67 2,76 LLLLEEEEE ANVGIVKGF 1,10
5 13 AAAGAVVGG 1PMH.pdb 124 132 2,74 LLLLEEEEE ANAGKKVKI 1,54
5 13 AAAGAVVGG 1TC5.pdb 164 172 2,77 LLLLLEEEL KYNSRVISG 2,03
5 13 AAAGAVVGG 2POH.pdb 178 186 2,75 LLLLLLLLL AATGTANKG 2,28
5 13 AAAGAVVGG 1K7I.pdb 338 346 2,76 LLLLEEELL VTIENAIGG 2,37
5 13 AAAGAVVGG 1WXC.pdb 110 118 2,80 LLLLEELLL STDGRVMDG 2,49
5 13 AAAGAVVGG 1CL8.pdb 121 129 2,58 HHLLLLELL IRNGLLVGK 2,63
5 13 AAAGAVVGG 1M1Z.pdb 8 16 2,65 LLLEEEEEE AAFGFLASA 2,81
5 13 AAAGAVVGG 1RUT.pdb 153 161 2,82 LLLLEELLL VGEPTLMGG 2,87
5 13 AAAGAVVGG 1QOY.pdb 196 204 1,22 LLLLEEELH AAAGVVVGP 2,93
6 14 AAGAVVGGL 1P5VB.pdb 36 44 2,74 LLLLEEEEE DTELLVGTL 1,91
6 14 AAGAVVGGL 1CL8.pdb 122 130 2,75 HLLLLELLL RNGLLVGKR 2,49
6 14 AAGAVVGGL 3TDT.pdb 159 167 2,77 LLLLEELLL SGGVGIGGV 2,56
6 14 AAGAVVGGL 1BO4.pdb 83 91 2,10 ELLEEEEEE DQEAVVGAL 2,71
6 14 AAGAVVGGL 3TDT.pdb 203 211 2,70 LLLLEELLL SMGVYLGQS 2,78
6 14 AAGAVVGGL 1C5E.pdb 39 47 2,24 LLLLEEEEE TDGAAVGIL 2,84
6 14 AAGAVVGGL 1ZQ1.pdb 110 118 2,60 LLLEEEELL ETGAVYPAF 2,96
6 14 AAGAVVGGL 1X38.pdb 49 57 2,86 LLLEEEELL FIGSLLSGG 3,04
6 14 AAGAVVGGL 1QRE.pdb 185 193 2,69 LLLLEEELL EPRSAAIGV 3,07
6 14 AAGAVVGGL 1IM3.pdb 19 27 1,79 EEEEEEELL ARGSIVGNM 3,08
7 15 AGAVVGGLG 1K7I.pdb 340 348 2,79 LLEEELLLL IENAIGGSG 1,50
7 15 AGAVVGGLG 2QSK.pdb 83 91 2,83 LLEEELLLL SGFCQGTAG 1,62
7 15 AGAVVGGLG 1ZKJ.pdb 262 270 2,74 ELLEEELLL VGGMTQGLG 1,62
7 15 AGAVVGGLG 2B4W.pdb 300 308 2,60 LLLEELLLE HGTIIGDLH 1,87
7 15 AGAVVGGLG 2C1L.pdb 331 339 2,64 LLEELLLLL AVSFIGNRG 1,89
 118  
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7 15 AGAVVGGLG 2FFY.pdb 259 267 2,76 ELLEEELLL TGDMYQGLG 1,89
7 15 AGAVVGGLG 1BF2.pdb 726 734 2,33 LLEEEELLL SETLIGGAG 1,92
7 15 AGAVVGGLG 1CL8.pdb 123 131 2,48 LLLLELLLL NGLLVGKRG 1,93
7 15 AGAVVGGLG 2Z8X.pdb 404 412 2,81 LEEEELLLL YNVILGGAG 1,99
7 15 AGAVVGGLG 2EHP.pdb 8 16 2,59 LLLEEELLL EGKVEGVPG 2,04
8 16 GAVVGGLGG 1XEZ.pdb 629 637 2,07 LLLEELLLL DLLVGGNGG 1,56
8 16 GAVVGGLGG 1BO4.pdb 85 93 2,46 LEEEEEEEE EAVVGALAA 1,68
8 16 GAVVGGLGG 2YVT.pdb 133 141 2,48 LEEEEEELL EFEVIGFGG 1,72
8 16 GAVVGGLGG 1VPS.pdb 210 218 2,83 EEEELLLLL GNYTGGTTT 2,14
8 16 GAVVGGLGG 1IM3.pdb 21 29 2,18 EEEEELLLL GSIVGNMSR 2,14
8 16 GAVVGGLGG 2EHP.pdb 9 17 2,67 LLEEELLLL GKVEGVPGN 2,22
8 16 GAVVGGLGG 1GVP.pdb 67 75 2,98 HEEELLLLL SFKVGQFGS 2,24
8 16 GAVVGGLGG 1XR4.pdb 387 395 2,12 LLELLELLL GVLRGASGG 2,41
8 16 GAVVGGLGG 2HS1.pdb 44 52 1,31 EEEEEELLE PKMIGGIGG 2,41
8 16 GAVVGGLGG 1BF2.pdb 727 735 2,86 LEEEELLLL ETLIGGAGT 2,46
9 17 AVVGGLGGY 2BMZ.pdb 53 61 3,02 EEEELLLLE RHYGGSGGT 0,87
9 17 AVVGGLGGY 1IM3.pdb 22 30 2,60 EEEELLLLE SIVGNMSRF 1,07
9 17 AVVGGLGGY 1XEZ.pdb 630 638 2,21 LLEELLLLE LLVGGNGGS 1,37
9 17 AVVGGLGGY 2YVT.pdb 134 142 2,31 EEEEEELLE FEVIGFGGL 1,58
9 17 AVVGGLGGY 1UF3.pdb 108 116 2,30 EEEEEELLE YLVAGVGGE 1,59
9 17 AVVGGLGGY 1BO4.pdb 86 94 2,49 EEEEEEEEE AVVGALAAY 1,62
9 17 AVVGGLGGY 1V0W.pdb 265 273 2,86 EEEELLLLL IAVGGLGVG 1,64
9 17 AVVGGLGGY 1IG0.pdb 187 195 2,24 EEELLLLLL LALGGIGGR 1,65
9 17 AVVGGLGGY 2HS1.pdb 45 53 0,57 EEEEELLEE KMIGGIGGF 1,72
9 17 AVVGGLGGY 1TT7.pdb 244 252 3,04 EELLLLLLL AVSGLTGGG 1,72
10 18 VVGGLGGYM 1IM3.pdb 23 31 2,50 EEELLLLEE IVGNMSRFV 1,23
10 18 VVGGLGGYM 1XEZ.pdb 631 639 2,50 LEELLLLEE LVGGNGGSL 1,30
10 18 VVGGLGGYM 2HAH.pdb 55 63 2,94 EEEELLEEE MIGGIGGFI 1,46
10 18 VVGGLGGYM 1G7S.pdb 265 273 2,97 EEEELLLEE AMMTSKDVI 1,80
10 18 VVGGLGGYM 1TYV.pdb 186 194 2,75 EEELLLLLE PSGGKDGII 1,84
10 18 VVGGLGGYM 1HRU.pdb 165 173 2,78 LLLLLLLLL VPGETGGRL 1,92
10 18 VVGGLGGYM 2HS1.pdb 46 54 0,12 EEEELLEEE MIGGIGGFI 1,96
10 18 VVGGLGGYM 1K7I.pdb 343 351 3,06 EELLLLLLE AIGGSGNDI 1,99
10 18 VVGGLGGYM 1G6S.pdb 74 82 2,74 EEELLLLLL EIIGNGGPL 2,01
10 18 VVGGLGGYM 2YVT.pdb 135 143 1,98 EEEEELLEE EVIGFGGLL 2,06
11 19 VGGLGGYML 1IM3.pdb 24 32 3,19 EELLLLEEE VGNMSRFVF 0,99
11 19 VGGLGGYML 1XEZ.pdb 632 640 2,51 EELLLLEEE VGGNGGSLS 1,23
11 19 VGGLGGYML 2Z43.pdb 137 145 3,06 HLLLLLEEE KGGLSGKAV 1,52
11 19 VGGLGGYML 1QQP.pdb 76 84 2,77 LLLLLLLLL FSGLFGALL 1,52
11 19 VGGLGGYML 1K7I.pdb 344 352 3,13 ELLLLLLEE IGGSGNDIL 1,60
11 19 VGGLGGYML 1HX6.pdb 61 69 2,97 LLEEEEEEE VGIVKGFLV 1,66
11 19 VGGLGGYML 1S1D.pdb 156 164 3,19 EELLLLLEE VGGLGKEWT 1,74
11 19 VGGLGGYML 1UUN.pdb 152 160 3,06 LLEELLLEE TGAAGGVLL 1,75
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11 19 VGGLGGYML 2Z8X.pdb 408 416 3,13 ELLLLLLEE LGGAGNNTL 1,92
11 19 VGGLGGYML 1TYV.pdb 187 195 2,99 EELLLLLEE SGGKDGIIT 1,94
12 20 GGLGGYMLG 2ARC.pdb 34 42 3,25 LLLLLEEEE LGMKGYILN 1,86
12 20 GGLGGYMLG 1UUN.pdb 153 161 3,24 LEELLLEEE GAAGGVLLR 2,09
12 20 GGLGGYMLG 1UYN.pdb 59 67 3,34 LLLEEEEEE GGVEGKMRG 2,12
12 20 GGLGGYMLG 2PGC.pdb 159 167 1,48 LLLLLEEEE SNVGNYLLG 2,14
12 20 GGLGGYMLG 1IKP.pdb 549 557 3,23 LLLEEEEEL GGRLETILG 2,25
12 20 GGLGGYMLG 1WRJ.pdb 127 135 3,14 LLLLLLLLL KSLGGYSRG 2,43
12 20 GGLGGYMLG 2BKX.pdb 124 132 3,27 LLLLEEEEL GDTDIQLLG 2,50
12 20 GGLGGYMLG 1U6E.pdb 182 190 3,30 LLELLLEEE QGIGPTVAG 2,55
12 20 GGLGGYMLG 1QFG.pdb 636 644 3,04 LLLLLEEEE GPLSGLTLG 2,71
12 20 GGLGGYMLG 1A73.pdb 33 41 2,99 LLEEEEEEE GGLQGTLHC 2,72
13 21 GLGGYMLGS 2IHO.pdb 241 249 3,18 ELLEEEEEE IFCGVMLGV 0,96
13 21 GLGGYMLGS 1TYV.pdb 319 327 3,16 LLLEEEEEE GVGFGMDGK 0,98
13 21 GLGGYMLGS 1KKO.pdb 352 360 3,17 LLEEEELLL GMEAYQGGT 1,47
13 21 GLGGYMLGS 2PGC.pdb 160 168 1,70 LLLLEEEEE NVGNYLLGV 1,58
13 21 GLGGYMLGS 1TYV.pdb 341 349 3,19 LLLEEEEEE GSGAYLLTH 1,58
13 21 GLGGYMLGS 2FOK.pdb 437 445 3,29 LLEEEELLL GYRGKHLGG 1,83
13 21 GLGGYMLGS 1A73.pdb 30 38 3,19 EEELLEEEE PLGGGLQGT 1,91
13 21 GLGGYMLGS 1U6E.pdb 183 191 2,86 LELLLEEEE GIGPTVAGS 1,91
13 21 GLGGYMLGS 1G6S.pdb 77 85 2,79 LLLLLLLLL GNGGPLHAE 1,97
13 21 GLGGYMLGS 1TYV.pdb 420 428 2,93 LLLLLLLLL GLGNIRANS 2,13
14 22 LGGYMLGSA 2PGC.pdb 161 169 1,65 LLLEEEEEE VGNYLLGVG 1,62
14 22 LGGYMLGSA 1TYV.pdb 205 213 3,15 LLLEEEEEE KGNYVIGGR 1,63
14 22 LGGYMLGSA 1ZXX.pdb 63 71 2,87 LLLLLLLLL VSGTFLYSA 1,87
14 22 LGGYMLGSA 2DEX.pdb 433 441 2,92 LLLEEEEEL LGRILFGDS 1,90
14 22 LGGYMLGSA 1WDD.pdb 165 173 3,32 LLLLEEELE YGRPLLGCT 1,96
14 22 LGGYMLGSA 2IHO.pdb 242 250 2,64 LLEEEEEEL FCGVMLGVN 1,97
14 22 LGGYMLGSA 1N7V.pdb 526 534 2,64 LLEEEEEEL GGVMFIGSA 1,98
14 22 LGGYMLGSA 2HIG.pdb 164 172 3,06 LLLLLLLLL YGGTILGSS 2,02
14 22 LGGYMLGSA 2B4U.pdb 274 282 3,06 LLLLLLLLL IGGFYYGEF 2,05
14 22 LGGYMLGSA 2R2C.pdb 78 86 3,07 LLLLLLLLE LEGNTLPKS 2,50
15 23 GGYMLGSAM 1VPR.pdb 245 253 3,10 LLEEEEEEE GGNLLGVWV 1,73
15 23 GGYMLGSAM 1WDD.pdb 166 174 3,01 LLLEEELEL GRPLLGCTI 1,79
15 23 GGYMLGSAM 2PGC.pdb 162 170 2,49 LLEEEEEEE GNYLLGVGY 1,92
15 23 GGYMLGSAM 1N7V.pdb 527 535 2,52 LEEEEEELL GVMFIGSAR 2,35
15 23 GGYMLGSAM 1V8C.pdb 116 124 3,02 LEEEELLEE GVYRLPGAV 2,36
15 23 GGYMLGSAM 1TYV.pdb 206 214 3,23 LLEEEEEEE GNYVIGGRT 2,60
15 23 GGYMLGSAM 1DGS.pdb 65 73 3,03 LLLLLLLLL GARPLEPTF 2,92
15 23 GGYMLGSAM 1HX6.pdb 125 133 2,82 LLLLLLLLL GAPFLSSMV 2,92
15 23 GGYMLGSAM 1EA5.pdb 118 126 2,13 LLLLLLLLL GGFYSGSST 2,93
15 23 GGYMLGSAM 2PS1.pdb 115 123 3,21 LEEEEELLL GGIIVGSAL 2,97
16 24 GYMLGSAMS 2DLB.pdb 3 11 2,86 LLLLLLLLL GYLNNIALN 1,28
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16 24 GYMLGSAMS 1ZK5.pdb 108 116 3,04 EEELLLLEE GWCVGNYVS 2,05
16 24 GYMLGSAMS 1GVE.pdb 75 83 2,80 LLLLLLLLL APMFGKTLK 2,67
16 24 GYMLGSAMS 1EOK.pdb 150 158 2,82 LLLLLLLLL GWYSGSMAA 2,76
16 24 GYMLGSAMS 1UN7.pdb 316 324 2,56 LLELLELLL GTLAGSILK 2,83
16 24 GYMLGSAMS 2CME.pdb 27 35 2,24 EELLLLLLL ILRLGSNLS 2,84
16 24 GYMLGSAMS 1SKZ.pdb 12 20 2,66 LLLLLLELL GCPEGSACN 2,89
16 24 GYMLGSAMS 1I4M.pdb 9 17 0,30 LLEELLLLL GYMLGSAMS 3,12
16 24 GYMLGSAMS 2IHO.pdb 244 252 2,67 EEEEEELLL GVMLGVNKA 3,14
16 24 GYMLGSAMS 1ORO.pdb 109 117 3,18 LLEEELLLL GNLVGSALQ 3,23
17 25 YMLGSAMSR 1BCP.pdb 50 58 3,18 EEEEEELLL FCFGKDLKR 2,31
17 25 YMLGSAMSR 2O3I.pdb 166 174 3,10 EEELLLLLL VELGVRMPP 2,37
17 25 YMLGSAMSR 2I0X.pdb 63 71 3,10 EEELLLLLL YKLRSMPPR 2,50
17 25 YMLGSAMSR 1XO0.pdb 228 236 2,97 LEELLLLLL VAAPSATSQ 2,72
17 25 YMLGSAMSR 2NW5.pdb 264 272 3,12 EEELLLLLL FVLNTYKSR 2,97
17 25 YMLGSAMSR 2EDM.pdb 103 111 2,77 EEELLLLLE NIKGNTMSN 2,98
17 25 YMLGSAMSR 2FJ0.pdb 461 469 2,94 LLLLLLLLL SMLGGHASF 3,03
17 25 YMLGSAMSR 2CME.pdb 28 36 2,17 ELLLLLLLL LRLGSNLSL 3,05
17 25 YMLGSAMSR 1WTH.pdb 356 364 3,19 EEEELLLLL YMFTNATKL 3,05
17 25 YMLGSAMSR 1QNX.pdb 119 127 3,13 EEEEELLLL ALTGSTAAK 3,15
18 26 MLGSAMSRP 1VLY.pdb 263 271 3,08 EEELLLLLL LAGSASRLP 1,74
18 26 MLGSAMSRP 1QB5.pdb 80 88 2,99 EEELLLLLL MCASPASSP 2,01
18 26 MLGSAMSRP 2O3I.pdb 167 175 3,15 EELLLLLLL ELGVRMPPP 2,10
18 26 MLGSAMSRP 1BCP.pdb 51 59 3,11 EEEEELLLL CFGKDLKRP 2,11
18 26 MLGSAMSRP 2FJ0.pdb 462 470 2,91 LLLLLLLLL MLGGHASFP 2,67
18 26 MLGSAMSRP 1SV6.pdb 165 173 3,12 EELLLLELL VIGGPAQRP 2,70
18 26 MLGSAMSRP 1K5N.pdb 7 15 2,98 EEEEEELLL YFHTSVSRP 2,76
18 26 MLGSAMSRP 2HWK.pdb 169 177 3,02 EEELLLLLL VVGEKLSVP 3,02
18 26 MLGSAMSRP 1BHP.pdb 32 40 2,90 EELLLLLLL KLTSGLSCP 3,02
18 26 MLGSAMSRP 1GVH.pdb 347 355 2,89 HLLLLLLLL KLEGAFSDP 3,11
19 27 LGSAMSRPI 1TTU.pdb 169 177 3,19 EEEEELLLE IGGFVSQRI 2,07
19 27 LGSAMSRPI 1L0W.pdb 100 108 3,11 EELLLLLLL LAEAKTPPF 2,19
19 27 LGSAMSRPI 1YM5.pdb 145 153 2,56 HLLLLLLLL IGLKFIKPP 2,22
19 27 LGSAMSRPI 1PSW.pdb 174 182 2,84 LLLLLLLLE FSLSSERPM 2,31
19 27 LGSAMSRPI 2I2C.pdb 191 199 2,26 LLLLLLLLE VYRTIGSPL 2,35
19 27 LGSAMSRPI 2PZM.pdb 262 270 2,39 HLLLLLLLL VGATLAEPV 2,41
19 27 LGSAMSRPI 1RVK.pdb 345 353 2,93 LELLLLLLE YLKSLSDPM 2,52
19 27 LGSAMSRPI 2GSJ.pdb 106 114 2,40 LLLLLLLLL GGRSSSRPL 2,70
19 27 LGSAMSRPI 2PH5.pdb 178 186 2,87 LLLLLLLLL NGLTINRPK 2,81
19 27 LGSAMSRPI 1UNL.pdb 138 146 2,63 HLLLLLLLL MGNEISYPL 2,82
20 28 GSAMSRPII 1EV2.pdb 104 112 2,90 LLLLLLLEE ERSPHRPIL 1,70
20 28 GSAMSRPII 1WWM.pdb 82 90 2,89 LLLLLLLLL GASPSAPVH 1,76
20 28 GSAMSRPII 1QHO.pdb 493 501 2,86 LLLLLLLEE STSASAPQI 1,77
20 28 GSAMSRPII 1VAV.pdb 108 116 2,75 LLLLLLEEE NSGQAAPLV 2,12
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20 28 GSAMSRPII 2I2C.pdb 192 200 1,96 LLLLLLLEE YRTIGSPLV 2,20
20 28 GSAMSRPII 1PSW.pdb 175 183 2,56 LLLLLLLEE SLSSERPMI 2,27
20 28 GSAMSRPII 2P1J.pdb 116 124 2,87 LLLLLLLEE GLDWERPYI 2,37
20 28 GSAMSRPII 2PZM.pdb 263 271 2,50 LLLLLLLLL GATLAEPVP 2,42
20 28 GSAMSRPII 1NZI.pdb 73 81 2,91 LLLLLLLLL SNNPHSPIV 2,54
20 28 GSAMSRPII 1URH.pdb 226 234 2,90 LLLLLLLEE GVSYDKPII 2,61
21 29 SAMSRPIIH 2CEO.pdb 342 350 2,87 LLLLLLEEE NTFLHPIIQ 1,16
21 29 SAMSRPIIH 1EV2.pdb 105 113 2,67 LLLLLLEEL RSPHRPILQ 1,62
21 29 SAMSRPIIH 1PPR.pdb 152 160 2,76 LLLLLLLLL TSAAGPATV 1,74
21 29 SAMSRPIIH 1VAV.pdb 109 117 2,94 LLLLLEEEE SGQAAPLVK 2,18
21 29 SAMSRPIIH 1ZK5.pdb 121 129 2,94 EEEEEEEEL SVHVRPVIL 2,23
21 29 SAMSRPIIH 1Q2L.pdb 240 248 2,79 LLLLLLLLL PEITVPVVT 2,28
21 29 SAMSRPIIH 1VLP.pdb 11 19 2,66 LLLLLLLLL HHMSEPVIK 2,39
21 29 SAMSRPIIH 2O28.pdb 23 31 2,75 LLLLLLLLL TATFSPAIS 2,39
21 29 SAMSRPIIH 1VRB.pdb 180 188 2,56 LLLLLLLLL ENVSNPMQH 2,42
21 29 SAMSRPIIH 2DXC.pdb 226 234 2,78 LLLLLLLLL VNAKRPVLK 2,43
22 30 AMSRPIIHF 1VI9.pdb 208 216 2,82 EEEEELLLL HISRPLVDF 1,47
22 30 AMSRPIIHF 2CEO.pdb 343 351 2,77 LLLLLEEEL TFLHPIIQI 1,56
22 30 AMSRPIIHF 1OHV.pdb 212 220 3,07 LLLLLEELL SFDWPIAPF 1,70
22 30 AMSRPIIHF 1EV2.pdb 106 114 2,76 LLLLLEELL SPHRPILQA 1,76
22 30 AMSRPIIHF 1D02.pdb 65 73 2,34 HLLLLLLLH EIFNPLIDL 1,82
22 30 AMSRPIIHF 2E67.pdb 70 78 3,07 LLLLLLLLL PRMRPLTEG 1,95
22 30 AMSRPIIHF 1JQN.pdb 435 443 2,72 HLLLLLLLL NSKRPLLPR 2,06
22 30 AMSRPIIHF 2O8B.pdb 735 743 3,17 LEELLEELL PMCRPVILL 2,22
22 30 AMSRPIIHF 1JFL.pdb 95 103 3,08 HLLLLELLH AIKIPIISM 2,24
22 30 AMSRPIIHF 2IJE.pdb 148 156 2,97 LLLLLLELL NCDPPCVPY 2,37
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